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Abstract 
 
Clinical trials (CT) are fundamental to develop new medicines. Clinical trials are the gateway 
between scientific research and clinical practice. These phases have great importance as they 
stand for a keystone for economy, providing patients with early access to innovative 
medicines.  
The aim of this dissertation is to study the Portuguese reality concerning clinical trials and to 
evaluate the number of clinical trials, submitted for approval in Portugal. The author also 
compares Portugal with other European Union (EU) member states, with United States of 
America (USA) and with emerging markets. The main objective is to find the reasons for the 
present situation and try to bring together the necessary alterations to change the negative 
trend. For this to occur it is important to understand the laws and regulations in this area 
and be acquainted with the main difficulties that the intervening elements face in a clinical 
trial (sponsors, investigators, clinical research sites, participants, Clinical Research 
Organizations, Authorities and Ethics Committee).     
Portugal has a strong potential growth in this area. However, in order to improve the 
Portuguese position in the clinical trial field, scientific and economic support is needed. 
Therefore, it is urgent to set Portugal at the heart of clinical research along with a 
competitive position within Europe.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
Resumo 
 
Os ensaios clínicos são uma etapa fundamental no desenvolvimento de novos medicamentos.  
Os ensaios clínicos são a ponte entre a investigação científica e a prática clínica adquirindo 
uma importância fundamental por serem a primeira oportunidade dos doentes acederem a 
tratamentos inovadores e por terem impactos económicos muito importantes. 
Com esta dissertação pretende-se analisar a situação portuguesa relativamente aos ensaios 
clínicos focando o número de ensaios realizados em Portugal, comparando Portugal com 
outros países, realçando as razões e os pontos críticos para a situação encontrada, 
destacando desafios e oportunidades e compilando algumas iniciativas possíveis e 
necessárias. Para tal é importante analisar o enquadramento regulamentar da investigação 
clínica e conhecer as principais dificuldades que sentem os intervenientes nos ensaios clínicos 
(Promotores, Investigadores, Centros de ensaios, Doentes, Clinical Research Organizations, 
Autoridades e Comissão de Ética), desde o início ao fim do ensaio. 
Portugal tem um grande potencial de crescimento nesta área que não pode ser desperdiçado 
para que a situação científica e económica evolua. É urgente colocar Portugal no centro da 
investigação clínica, com uma posição de destaque na Europa. 
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I. Clinical Trials Introduction 
I.I. Role of Clinical Trials in Medicines Development 
Clinical research can be grouped in interventional studies (clinical trials) and non-
interventional studies (observational studies). This dissertation focuses on clinical trials only. 
Clinical Trials can be defined as any type of investigation on human-beings in order to 
discover or verify the clinical, pharmacological and/or pharmacodynamic effects of any 
medicinal product, its adverse reactions and also study its absorption, distribution, 
metabolism and excretion [1].  
Regulatory entities such as European Medicines Agency (EMA) and the Food and Drug 
Administration (FDA) in the United States are responsible for establishing procedures and 
rules for drug testing and to ensure their implementation. Some of these regulations will be 
referred to below.  
Clinical trials can be classified according to their clinical development phase or by their 
objectives (Figure 1). Initial human pharmacology trials provide an early evaluation of short-
term safety and tolerability and can provide pharmacodynamic and pharmacokinetic 
information needed to choose a suitable dosage range and administration schedule. Usually 
they are followed by therapeutic exploratory studies in relatively small groups of patients 
with the target indication. Later confirmatory studies are generally larger and longer and 
include a more diverse patient population. Dose response information should be obtained at 
all stages of development. Figure 1 demonstrates the correlation between the two 
classification systems [2].  
 
 
 
 
 
 
 
 
 
Figure 1: Correlation between the development phases and the types of studies. The shaded 
circles represent the types of study most usually conducted (by phase) and open circles show certain types of 
studies that may be conducted, but are less usual. Each circle represents an individual study that includes the 
objectives, design, conduct, analysis and report.  Adapted from source [2]. 
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As can be seen, the types of studies are not exactly synonymous with the phases of 
development because the typical temporal sequence, described by phase concept, is not 
appropriate [2]. 
All new medicines are the result of a long, costly and risky research and development (R&D) 
process. From the synthesis of a new active substance to marketing approval, an average of 
12-13 years will have elapsed. Of every 10,000 substances, only one or two will successfully 
be marketable medicines. The investment in the conduct of clinical trials represents two-
thirds of the cost of developing a new drug (Figure 2) [3].  
 
 
 
 
 
 
 
 
 
 
Figure 2: R&D investments. Allocation of R&D investments by function (%). The investment in the 
realization of CT represents two-thirds of the cost of developing a new drug. Reproduced from source [3]. 
 
The high investment in clinical trials, the long development phase and thousands of 
substances failed and abandoned make the development of a new drug a high risk enterprise, 
as seen in Figure 3 [4]. 
 
 
 
 
 
 
 
 
Figure 3: Probability of commercialization. During the research phase of a new drug, the probability of 
commercialization is residual. In phase I and II the probability increases but only achieves 25%. Even at the time 
of submission the probability of commercialization is just round 80%. Adapted from source [4]. 
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The final objective of clinical trials is to turn fundamental research into innovative treatments 
that can be widely available and accessible to people, resulting in increased life expectancy 
and improved quality of life [3]. For this to happen it is important to articulate the work of 
all stakeholders involved in clinical trials.  
 
 
 
 
 
 
 
 
 
 
Figure 4: Key group of stakeholders. Stakeholders involved in CT. Reproduced from source [5]. 
 
The sponsor is the entity responsible for the implementation and financing of a clinical trial. 
The sponsor can be an individual, company, institution or organisation [1]. Pharmaceutical 
companies, the most common sponsors, run in-house clinical trials and/or can outsource 
(contract an independent organisation to perform tasks) those as well. Contract Research 
Organizations (CROs) are organizations solely focused and specialized on clinical trials in 
order to respond to the growing complexity of clinical trials and to improve efficiency in this 
process [5]. They are sought by sponsors to improve efficiencies, flexibility and to find 
specific expertise [6]. 
Healthcare Centres and Hospitals are the sites where clinical trials are conducted. On these 
sites there are researchers/doctors who are the leaders of the clinical trial [5]. Related to 
sites, a Site Management Organization (SMO) is a stakeholder that provides clinical trial 
related services to CROs or directly to sponsors and has the purpose of organizing sites, 
giving formation to researchers and human resources of the site, implementing harmonized 
procedures, studying the capacity of sites in terms of patients and clinical areas, and creating 
a network of sites with forms of action and competences harmonized.  
In the end we have the authorities and the patients. The authorities have the responsibility of 
approving/rejecting the start of a clinical trial, taking into account what is the best for 
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patients as well as the compliance with laws and ethics. Patients are people that voluntarily 
agree to take part in the clinical trial [5].    
Clinical trials are important for all stakeholders. For the clinical investigator, these trials are 
the door to new scientific discoveries and they enhance both national and international 
visibility. For industry, they can represent new medicines in the market and new business 
opportunities. Finally for participants, clinical trials represent a change of early access to new 
and better medicines and the improvement of medical support [7]. Clinical trials mean also 
creation of new jobs and taxes payment. Consequently, they improve the commercial 
balance reducing public expenditure and inducing value in all activities for the whole chain 
[8]. The following figure represents key benefits of clinical trials.       
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Top 5 advantages of clinical trials. The advantages of the conduct of clinical trials are 
transversal to all stakeholders. The main advantage is the access to new therapies for patients. Note: Multiple 
answers available - results do not sum up to 100%. Reproduced from source [5]. 
 
 
Besides all advantages mentioned above, clinical trials can also have a short-term impact on 
the economy of the city or even the country where they are performed.  The 
economic/financial impact of clinical trials is evident during the interaction of the various 
stakeholders, as can be seen in Figure 6. 
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Figure 6: Key impacts on the local economy. The economic/financial impact of clinical trials is evident 
during the interaction of the various stakeholders. $ is a symbol of a cash flow. Reproduced from source [5]. 
 
There are many factors that influence the choice of where to conduct clinical trials. The 
location of key partners, access to trial site, internal facilities, future product launches, 
patient availability, cost efficiency, relevant expertise, regulatory conditions, approval 
timelines, national infrastructure and market potential are some of the factors that 
pharmaceutical industry have to take into account when they have to choose a country [9]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Global key drivers for clinical trial location choice. There are many factors that influence 
the choice of where to conduct clinical trials. Approval timelines, access to patient populations, relevant 
expertise and cost are the most important factors that sponsors have to take into account when they have to 
choose a country, according to PwC analysis. Reproduced from source [6]. 
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It is also important to evaluate the interest and ability of the sites to perform a particular 
clinical trial. For this to occur there is the Feasibility Questionnaire (FQ), which is a small 
questionnaire that sponsors send to the putative study sites. In this questionnaire the site is 
required to give information about the physicians with interest in the study, the number of 
patients that can be recruited for the study and other important information. 
One of the most important steps of this process is the recruitment of patients. The 
consequences of a poor recruitment are transversal to all stakeholders. For sponsors it may 
cause potentially twisted statistical results, loss of position and/or revenue for product and 
decline of confidence in investigators. For sites it may bring potential lost revenue for 
missing targets, risk to future trial participation with sponsor and loss in patient confidence 
[10].  
There are many factors that influence the recruitment and many reasons to participate in a 
clinical trial. A 2004 European survey found that 68% of the people interviewed would 
consider joining a clinical trial and two-thirds were motivated “to advance medical science”. 
The other reasons were:  “help others with condition” (57%), “obtain better treatment for 
my condition” (48%) and “obtain faster access to treatment for my condition” (34%). The 
main reasons for the decline in participation were believed to be: medical treatment would 
be less effective than standard care, they might get a placebo and they would be treated like 
a “guinea pig”. Travel distance and out-of-pocket expenses were also referred [10]. 
The aim of this dissertation is to study the Portuguese reality concerning clinical trials and 
evaluate the number and type of clinical trials submitted for approval in Portugal together 
with their evolution. The author intends also to compare Portugal with other EU member 
states (MS), with USA and with emerging markets. The main objective is to find the reasons 
for the present declining situation and try to bring together the necessary alterations to 
change the negative trend. For this to occur it is important to understand the laws and 
regulations in this area and be acquainted with the main difficulties that the intervening 
elements face when implementing and conducting a clinical trial.     
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I.II. Historical Perspective 
 
The first reference to health experiments dates back to 605 BC. Old Testament explains 
how Daniel did an experiment when he refused the diet ordered by King Nebuchadnezzar 
[11]. However, we can tell that James Lind conducted the first CT in May 1747. After two 
months at sea, when the ship was afflicted with scurvy, he controlled a group of 12 sailors 
with scurvy and divided them into six pairs, giving each group different additions to their 
same basic diet. With this experimentation Lind established the treatment for scurvy [12]. 
This clinical trial is a relevant milestone for clinical research and the reason why, today, the 
International Day of Clinical Trial is celebrated in May. After that, clinical trials have been 
suffering a substantial evolution. 
The concept of placebo was introduced in clinical trials as early as in 1799, when John 
Haygarth conducted a clinical trial with a group of control he named placebo-controlled. 
However, it was only in 1832 that placebo took on its current meaning of a treatment that 
has no medical value except psychologically [13]. In 1944 Multicenter Clinical Trial (MCT) 
was introduced. This is a clinical trial carried out according to a single protocol at more than 
one medical centre or clinic. MCT is conducted by more than one investigator at several 
sites. The advantages of these trials are that they include a larger number of participants, 
different geographic locations and the ability to compare results between centres [1, 14]. 
It is also important to understand the facts that are in the origin of the ethical concerns and 
evolution. As early as in 1803 we have references to “Code of Ethics”, which can be 
considered the beginning of ethical concerns. In this year Thomas Percival advised physicians 
to consult colleagues before trying new medicines and treatments. In 1847, the American 
Medical Association adopted a code of ethics and in 1902 the book “Medical Ethics” by 
Albert Moll was edited. After that, the concerns about ethics have improved but only in 
1945 were these concerns materialized in a strict regulation resulting in the Nuremberg 
Code and Helsinki Declaration. These regulations also resulted from the horror at the 
abuses perpetrated during the World War II and the Nazi human experimentations [13]. 
Nuremberg Code was created in the wake of the trial of Nazi doctors and it was the first 
internationally-recognized code of ethics for human research. It establishes ten basic 
principles for Human protection, centred not on the physician but on the research subject. 
These principles included an absolute requirement of voluntary informed consent, minimizing 
risks to subjects, results that are valuable to society and a new right of the subject to 
withdraw from participation in an experiment. The key contribution of Nuremberg was to 
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the combination of Hippocratic ethics with the protection of human-rights. Nuremberg 
Code has influenced global human-rights law and medical ethics [15]. 
The references to informed consent in medical treatment are much older than clinical 
research, dating back to 1767 when English court rules considered that informed consent 
should be prior to medical treatment. Medical treatment influenced the clinical research and 
the adoption, by the American Medical Association, in 1946, of a code of ethics for research 
on human-beings that required informed consent. These requirements were intensified in 
1962 after the Thalidomide disaster, when it was required to pharmaceutical companies to 
prove drug efficacy, firms to submit adverse reaction reports to the FDA, drug advertising to 
include complete information about risks and benefits, and informed consent from clinical 
study subjects [13]. 
In 1964 the World Medical Association (WMA) developed the Declaration of Helsinki, 
which also required informed consent. In contrast to the legal form of the Nuremburg Code, 
it takes the form of ethical guidelines [16]. The difference is that the Nuremberg Code 
focuses on the human-rights of research subjects while the Declaration of Helsinki focuses 
on the obligations of physician-investigators to research subjects. For example, it refers that 
medical research is subject to ethical standards that promote respect for all human-beings 
and protect their health and rights especially for research populations that are vulnerable 
and need special protection like those who cannot give or refuse consent for themselves 
[15]. However, only in 1967 did the FDA issue a policy clarifying that informed consent must 
be in writing. By this time, the discussion about this theme was very intense. The book 
“Human Experimentation: Ethics in the Consent Situation” (discussing issues of informed 
consent or lack thereof) by John Fletcher, was written and the Public Responsibility in 
Medicine and Research/Applied Research Ethics National Association (PRIM&R/ARENA) was 
founded. Also in 1982 the Council for the International Organization of Medical Sciences 
(CIOMS) published the “International Ethics Guidelines for Biomedical Research Involving 
Human Subjects”, including cross-cultural guidance for conducting research in developing 
countries, which were updated in 1993. In 2000, the World Health Organization (WHO) 
issued the "Operational Guidelines for Ethics Committees that Review Biomedical Research” 
[13]. In 2002, CIOMS prepared, in collaboration with the WHO, a new version of the 
“International Ethics Guidelines for Biomedical Research Involving Human Subjects” that 
overtook the guidelines of 1993 and whose core consists of 21 guidelines [17]. 
Modern ethics for research in humans are based on 3 pillars: Nuremberg Code, Helsinki 
Declaration and International Ethics Guidelines for Biomedical Research Involving Human 
Subjects of CIOMS and WHO. In order to standardize the questions related to clinical trials 
23 
and the requirements to approve a new medicine, it was created, in 1990, the International 
Conference on Harmonization (ICH), which is unique in bringing together the regulatory 
authority of USA, EU and Japan. Since its origin, the ICH has evolved to respond the 
increasingly global aspect of drug development and the benefits of international 
harmonization that ensure that safe, effective and high quality medicines are developed and 
registered in the most resourceful-efficient manner. Six years later, the ICH published 
“Good Clinical Practices: Consolidated Guideline” that is considered the Bible for 
conducting clinical trials [18]. 
In 2001, the Directive 2001/20/EC was put into practice and was introduced in the 
legislation of all Member States until 2004. This directive will deserve further analysis ahead 
in this dissertation [1]. 
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II. Clinical Trials Regulatory Framework   
 
As a result of some milestones aforementioned, clinical trials have, today, a strict regulation.  
The directive elaborated by the European Parliament in order to approximate laws, 
regulations and administrative provisions of all MS, related to the implementation of good 
clinical practice in the conduct of clinical trials on medical products for human use, is 
Directive 2001/20/EC [1]. This directive brings specifics rules on CT at the EU level. All CT 
are concerned except “non-interventional” studies [19]. 
In Portugal the Law nº 46/2004, of 19 August, establishes the legal regime applicable to the 
conduct of clinical trials with medicines for human use and it transposed into the national 
legal order the Directive 2001/20/EC [20]. This legislation repealed the Decree-Law nº 
97/94, of 9 April, but continues to reiterate the emerging internationals principles with more 
relevance for biomedical investigation in human-beings, with an emphasis on the Nuremberg 
Code, Declaration of Helsinki and International Ethics Guidelines for Biomedical Research 
Involving Human Subjects (of CIOMS and WHO (2002)) [21]. 
These principles are [15-17]: 
- Protect the life, health, privacy and dignity of the human-beings; 
- The subjects must be volunteers and have to be informed in one’s language or 
another form of communication that the individual can understand; 
- The voluntary consent of human subject is absolutely essential and must not be 
obtained by pressure, intimidation or payment; 
- The interests of the participants have always to prevail over those of science and 
society; 
- The physician shall act only in the patient’s interest and has to be qualified persons 
able to ensure that potential benefits and risks are reasonably balanced and risks are 
minimized; 
- The investigator must establish secure safeguards of the confidentiality of subject’s 
research data; 
- The participants have the right to treatment and compensation in case of injury. 
Compared the Law nº 46/2004 with previous regime, this new law brought some new 
aspects.  
To INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde I.P.) it was 
attributed, through its administration, the power to authorize the conduct of a clinical trial, 
within a period of 60 days. During this period, INFARMED has to analyse the required 
documentation sent by the sponsor and conclude that benefits to participants outweigh the 
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risks. If it is a MCT carried out in more than one country, it is necessary to have 
identification and approval of all competent authorities. The period of 60 days could be 
suspended due to requests for additional information or documentation and even extended 
for special cases when the investigational medicinal product is of biological origin, gene 
therapy, somatic cell therapy medicinal products, genetically modified organisms and 
xenogeic cell therapy medicinal products. For the first four, the evaluation period can be 
extended for more 30 or even 90 days. For the last one there is no deadline. On the other 
hand, the authorization can be granted tacitly if INFARMED does not provide the sponsor 
any negative opinion [21].  
Asking the permission is an attribution of the sponsor and it has to present its complete 
identification, the identification and qualification of all the researchers and members of the 
clinical trials’ team, information about the site of realization of clinical trial, protocol, 
investigator’s brochure and the dispositions about indemnities or compensations for possible 
test damage, insurances to cover the liability of both the investigators and the sponsor and 
other relevant elements of the financial contract between the sponsor and the trial site [21]. 
With this legislation INFARMED came to hold the competence to allow clinical trials, instead 
of to being only informed [21]. INFARMED is also the authority responsible for the 
inspections of GCP (Good Clinical Practices) and GMP (Good Manufacturing Practices). 
INFARMED inspectors are empowered to inspect all sites and resources involved in a 
clinical trial and the sponsor should ensure that they are always ready to be inspected. 
Failure to comply the terms of law could lead to criminal prosecution of the violator [19]. 
INFARMED is also the entity that can introduce the national data in EudraCT European 
database and the responsible for the creation of a data base on clinical trials conducted in 
national research centres [21]. 
The new law reiterates the general conditions for the participation and protection of 
subjects required in previous legislation. Without complying with the following requirements 
the clinical trial performance is not possible [1, 21]:  
- The researcher must clearly inform the participants about the objectives, risks and 
inconveniences of that type of research, about the conditions of the accomplishment 
of that clinical trial and must also give the participants right to quit the study at any 
time, using appropriate language adapted to the capacity of the subject; 
- The written declaration of informed consent; 
- The assure the integrity and the right to privacy and data protection; 
- The assure the right to medical treatment and care by a qualified doctor; 
- A contact point where subject may obtain further information; 
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- An insurance or indemnity to cover the liability of the investigator and sponsor, 
independent of guilty. 
Despite the fact that the previous law also obliges the existence of insurance to compensate 
the subject, the present law specifies the scope of insurance and clarifies some doubts when 
it expresses that all health damage of participant during the clinical trial and one year after its 
conclusion are attributable to clinical trial. However, this insurance doesn’t absolve the 
sponsor, the investigator and all team members of their civil and legal responsibility [21]. 
For ethical reasons, this legislation has special regulations to protect participants with less 
autonomy because of immaturity or mental perturbation. To include persons incapable of 
giving informed legal consent it is necessary [19, 21]: 
- The clinical trial has to bring some direct benefit for the participants and this have to 
be thoroughly evaluated by Ethics Committee for Clinical Research; 
- The clinical trial has to be directly related to a clinical condition of the participant and 
is essential to validate data obtained in clinical trials on persons able to give informed 
consent; 
- Requirements should be taken to minimize pain, fear, risk and distress; 
- The informed consent of a legal representative that should reflect the desire of the 
participant according to his/her capacity of understanding; 
- No financial benefits are allowed. 
In contrast to the previous law, the Law nº 46/2004 only refers to the prohibition of financial 
benefits to participants incapable of giving informed legal consent. Relative to capable 
participants this information is omitted [21]. 
There are other issues that this law doesn’t specify, such as the use of placebo and the 
participation of healthy people in clinical trials [21]. 
Despite the fact that the Helsinki Declaration accepts the use of placebo only if no proven 
prophylactic, diagnostic or therapeutic method exists, in this law there is only one reference 
to placebo that is the definition of the concept [16]. 
About the participation of healthy people, this legislation doesn’t make any reference to the 
status of healthy people who want to participate in clinical trials. The previous legislation had 
a restriction and said that healthy people could only participate if there were no risks to 
physical and psychic integrity of the participant. This legislation only refers that the potential 
benefits to participants have to overcome the risks and inconvenience [21]. 
Another change brought by the present legislation (and Directive 2001/20/EC) was the 
creation of an Ethics Committee for Clinical Research (CEIC) that has a crucial role in the 
approval of clinical trials. It is constituted by health professionals and other people that have 
 
 
28 
technical competencies to evaluate the clinical trial and the conditions for its 
accomplishment. CEIC has the responsibility of receiving and validating the request for the 
CEIC opinion presented by sponsor and take a decision about the clinical trial or substantial 
changes. CEIC can delegate the issuance of the opinion to another ethics committee 
designated Ethics Committee Competent (CEC). Only one opinion is required by law 
(opinion by CEIC or opinion by any CEC designated by CEIC by explicit delegation). 
Therefore, the authorization for conducting the clinical trial is independent from the 
existence of ethics committees in the entity seeking clinical trial [21]. CEIC or its delegate 
has 60 days to evaluate and issue an opinion about clinical trials, with an extension of 30 days 
if there is a request for further information [19].  
Concerning the protection of individuals with regard to the processing of personal data and 
on the free movement of such data, the European Parliament has published the Directive 
95/46/EC [22]. The Portuguese legislation that transposes this directive into the national 
legal order is Law nº 67/98, of 26 October, that establishes particular rules. This law states 
that the treatment and registration of personal data must respect the privacy and 
fundamental rights, freedoms and guarantees of the individual. The treatment of health data 
is forbidden except by authorization of National Commission for Data Protection (CNPD) 
and with express voluntary consent of the human subject. CNPD has also to authorize the 
interconnection of personal data. Therefore, the sponsor has to notify CNPD before the 
beginning of the clinical trial to obtain the authorization for the treatment, registration and 
interconnection of the data resulting from clinical trial [23].        
About investigational medicinal products, those haven’t been given any special treatment 
until this legislation but have now a chapter where all demands and obligations are defined. 
The manufacturing and import of those medicines have to be authorized by INFARMED and 
have to be according to the GMP. The authorization holder has to possess a qualified 
pharmacist responsible person for the medicine. Every control and registration related to 
medicine must be available. In this law, there is also a description of some rules to proceed 
to the labelling of the investigational medicinal product [20]. Finally it is important to detach 
the free availability of the experimental medicine to participant after the end of clinical trial 
since it is essential to continue treatment and there are not therapeutic alternatives [21]. 
Clinical trials have to respect every rules, directive and laws summarized above and they 
have to be made by investigators who have qualifications and GCP training or experience 
obtained from work with clinical trials and recognised by INFARMED and CEIC. In the 
procedure to notification a clinical trial, the sponsor must obtain a EudraCT number, 
according to Detailed Guidance on the European clinical trials database [24]. The competent 
29 
authorities and the ethics committee notified by coordinator, sponsor or investigator will be 
alerted about the study. This notification can be done in parallel or sequentially [19]. The 
sponsor may not start a clinical trial until the CEIC has issued a favourable opinion and 
inasmuch as the competent authority concerned has not informed the sponsor of any 
grounds for non-acceptance [24]. 
Whenever necessary, protocol amendments that meet the criteria for substantial 
amendments can be done and must be reported to the relevant competent authorities and 
ethics committees. Directive 2001/20/EC refers only amendments to the approved protocol 
and considers substantial amendments when they have a significant impact on the safety or 
physical or mental integrity of the clinical trial participants and/or the scientific value of the 
trial. It is up to the sponsor to assess whether an amendment is to be regarded as 
substantial. The Directive 2001/20/EC doesn’t establish a deadline for authorities’ response 
to the amendments. However they are invited to respond also within 35 days [24].  
For the end of the trial it is necessary to notify the competent authorities via EudraCT 
database within 90 days of trial completion or 15 days of premature termination [19].  
In Portugal, the INFARMED has a National Platform for Clinical Trials (PNEC) where, in the 
near future, the application for authorization of clinical trials, respective amendments and the 
information of the end of the trial can be submitted electronically [25]. 
Clinical trials may only be conducted in clinical investigative sites with adequate facilities and 
human resources. The responsibilities are exactly the same for clinical trials sponsored by 
pharmaceutical industry and those whose sponsors are the investigators who perform the 
clinical trials [19]. 
The approval process of clinical trials in Portugal can be summarized in the flowchart 
presented in Figure 8. After sponsor analysing the clinical trial feasibility, it is necessary to 
submit the clinical trial to the approval by INFARMED, CEIC and CNPD. 
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Figure 8:  Approval process for clinical trials in Portugal. Representative flowchart of the approval 
process of clinical trials in Portugal. Adapted from source [8].  
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III. Clinical Trial Trends 
 
The aim of this chapter is to compile the most important data of clinical research and clinical 
trials in Portugal. To better understand these data the author starts to frame Europe in the 
World. In sub-chapter III.I will be presented comparative data of Europe and the rest of the 
World, in sub-chapter III.II comparative data from Portugal and other similar countries and 
in sub-chapter III.III the data are related to the evolution of clinical research and clinical trials 
in Portugal, an overview.     
 
III.I. Europe vs Other Regions 
 
In Europe, the pharmaceutical industry has a significant role in R&D investment. However, 
the sector faces real challenges because it has been severely hit by the impact of fiscal 
austerity measures introduced by governments across much of Europe that resulted in 
pharmaceutical companies R&D spending decline [5].  Figure 9 shows the pharmaceutical 
R&D investment in Europe comparing with USA and Japan.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Pharmaceutical R&D investment in Europe, USA and Japan (1990-2011). 
Representative graphic of pharmaceutical R&D investment in Europe, USA, Japan and other countries. The 
same trend of the previous graphic. Reproduced from source [3].  
 
One of the major reasons for the investment decrease in Europe is the price control of 
medicines that are not ruled by free competition laws, but fixed by the governments on a 
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national basis [6]. However, stricter regulatory approval processes and efforts to contain 
healthcare expenditures have had a tendency to restrict the growth of markets in Europe. 
This has resulted in a lucrative parallel trade between countries with significant price 
differences. 
These countries are known by emerging markets [26]. Emerging economies such as Brazil, 
Russia, India and China (BRIC) have lived a rapid growth in the pharmaceutical market and 
research environment. In 2011 the Brazilian and Chinese markets grew 20.0% and 21.9% 
respectively, compared with an average market growth of 2.6% for the five major European 
markets and 3.6% for the USA market [3]. Europe has been losing competitiveness 
compared to others regions of the World and it is anticipated that markets in the emerging 
countries will continue to grow another 14-17% by 2014, compared with 3-6% for 
developed markets [6]. 
The investment in R&D has influence in the knowledge obtained and can influence the 
number of new medical entities. In the graphic below can be analysing the evolution of new 
medical entities in Europe, USA and Japan. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: New medical entities (1992-2011). Representative graphic of new medical entities in 
Europe, USA, Japan and others. Reproduced from source [3].  
 
Figure 10 highlights how the number of new discoveries has been decreasing in Europe. This 
reduction occurred even in years where the R&D investment in Europe increased. The R&D 
investment hasn’t been translated into new medicines. This is a problem called Translational 
Gap and it occurs when a lot of R&D investment results in a lot of scientific information that 
is not translated in applied knowledge and new products [27]. 
33 
Faced with an increasingly competitive market and an urgency to reduce costs and difficulties 
of medical product development, the actual development model has to be changed to a 
more flexible process, based on data [28]. This new model is supported by main regulatory 
authorities, including FDA, and it has the aims to ensure that, without prejudice of safety, the 
new drugs can be experienced in human-beings the earliest possible [29]. As can be seen on 
Figure 11, the new drug development process is expected to be shorter. More emphasis will 
be given on laboratory research (molecules) and on the robustness of the mechanism and 
safety of the molecules so that the drug development can be secure and launch “in-life 
testing”, that is a series of small, highly targeted clinical studies. The clinical trials will be 
more focused on a particular group of patients and the company will be allowed to market 
the drug on a restricted basis (to a narrow group of patients), upon the regulatory agency’s 
conditional approval [5]. 
 
 
 
 
 
 
 
 
 
Figure 11: Drug development process comparison. Comparison between current drug development 
process and the expectation for the future. The new development model is a more flexible process and based 
on data. Reproduced from source [5]. 
 
This new model has to reflect the new paradigm of actuation in the market that is highly 
affected by: level of market uncertainty, financing difficulties, new markets, high level of 
current market consolidation that leads to reduced growth opportunities, great competition 
from generics, aging population and pressure to reduce costs in health systems [8].  
Talking specifically about the conduct of clinical trials, the effort of developing new drugs can 
be tracked, based on worldwide pharmaceuticals pipelines. Analysing the state of these 
projects, the drugs in development can be known. The trend was year-on-year increases, 
since 1995. However, in 2011, the total of 9713 drugs in development represented a small 
decline (0.2%) from the 2010 number of 9737. This decline is insignificant but it would 
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appear to confirm a trend of a plateauing off the longer-term trend of year-on-year increases 
[4]. This results from the Translational Gap but is also consequence of a change in the good 
enough concept. “Ten years ago, if you had a drug that was a little bit better or even as good 
as something already on the market, you could get it approved. Those days are gone.” 
Jonathan Knowles (Chairman of the Innovative Medicines Initiative, Head of Research at 
Roche) [4]. This fact and also the financial restrictions had as consequence the review of all 
ongoing pipelines by the worldwide companies and the rejection of the unpromising projects 
that can be also contributed to the plateau phase. 
When examined the drugs in active development on a phase-by-phase basis, there are 
encouraging signs. Figure 12 represents the evolution of the number of drugs in active 
development since 2007 until 2011. There are now more R&D projects than ever before in 
clinical trials and all phases saw solid growth. The most robust growth was in phase III. The 
number of drugs in phase III, in 2011, has shown the biggest year-on-year jump so far 
recorded, with more 83 than 2010 (13%). This is a positive signal that appears to change 
recent trend of increases in the numbers of phase 1 and II drugs that failed to transition to 
phase III [4].  
Figure 12: Drugs in active development phase-by-phase (2007-2011). There are now more R&D 
projects than ever before in clinical trials and all phases saw solid growth. The number of drugs in phase III, in 
2011, has shown the biggest year-on-year jump so far recorded with more 83 than 2010 (13%). Adapted from 
source [4]. 
 
The investment in clinical trials represents two-thirds of the cost of developing a new drug.  
In 2009, it corresponded to reinvestment of an average of 18% of European pharmaceutical 
companies’ sales into R&D. The percentage share of total R&D budget allocated to clinical 
trials has increased considerably over the last few years due to the complexity of clinical 
trials [6]. 
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Figure 13: R&D investments allocated to clinical trials in Europe (2006-2009). The percentage 
share of total R&D budget allocated to clinical trials has increased considerably over the last few years due to 
the complexity of clinical trials. Reproduced from source [6].  
 
Rising costs and increasing budget pressures have started to affect clinical trials forcing 
companies to rethink how to perform these activities. The choice of the country that best 
suits the clinical trial is an increasing concern of the pharmaceutical companies. Depending 
on the location, cost saving can range from 30 to 65% in emerging markets compared with 
sites in the United States of America (USA) or Western Europe (WE). Also in these 
countries the time to complete clinical trials phases is shorter, which provides earlier relief 
to patients, a faster return on investment, a potential edge over competitors and a longer 
patent protection [9]. 
In 2006, the country attractiveness index for clinical trials was developed based on patient 
availability, cost efficiency, relevant expertise, regulatory conditions and national 
infrastructures and it considered USA, China and India as the most attractive locations [9]. 
For China to be on the top of this ranking (after USA), several factors were taken into 
account: the vast patient pool and large infrastructure of the hospitals, the large number of 
health professionals and their low salaries. India comes in second because it offers vast 
population, a growing market, the capabilities and experience of the country’s scientists, 
English as primary language and the incentive to promote local pharmaceutical companies 
and attract foreign firms [9]. Emerging countries are attracting clinical trials due to low costs 
and the availability of a skilled R&D workforce and of large patient population [6]. 
However, there are many risks in low-cost countries that companies have to consider and 
that make pharmaceuticals think before choosing one of these countries. They have to: 
protect intellectual property, know the regulatory requirements and learn the ethnicity and 
understand cultural differences (that varies widely from country to country) [9]. 
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To better understand how these parameters have been affected the clinical trials, we can see 
in the Table 1 and Figure 14 the actual number of clinical trials in Europe and in other 
continents. The data below were obtained by a research carried out on web site 
clinicaltrials.gov. Making an advanced search with only one criterion, the time of first 
received. So, for the year 2010 the timeline was put between 01/01/2010 and 12/01/2012. 
The same strategy was followed for 2011 and 2012. To 2013 the timeline between 
01/01/2013 to 06/30/2013 was considered. 
 
Table 1: Number of CT approved in the World (2010-2012), registered at clinicaltrials.gov. 
Adapted from source [30].  
 
 Canada USA South 
America 
Europe Africa North 
Asia 
Middle 
East 
South 
Asia 
East 
Asia 
Pacifica 
2010 1240 7310 674 5477 396 370 872 414 1926 439 
2011 1254 7305 739 5748 391 390 864 324 2176 444 
2012 1350 7550 694 6045 446 329 826 361 2375 415 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Clinical trials in the World (1st semester 2013). Representative graphic of the number of 
clinical trials distributed by the World in first half of 2013, registered at clinicaltrials.gov. Reproduced from 
source [30].  
 
The numbers represent a small variation in CT number performed in Europe. Despite the 
R&D investment decline, graphics represent a slight increase in CT numbers. However, this 
can be result of an improvement of data coverage by clinicaltrials.gov and can be a fictitious 
increase [31].   
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III.II. Portugal vs Other Countries 
 
After analyzing the clinical trials trend in Europe, it is important to check the Portuguese 
situation. If, by 2011, Europe had a small average market growth of 2.6%, Portugal hadn’t 
seen any growth and the evolution was negative. As can be seen on Table 2, on the top 50 of 
market growth from 2007 to 2011, Portugal appeared in 44th with a average market growth 
of -3.97% behind countries like Austria, Belgium and Czech Republic whose markets grew of 
27.19%, 18.61% and -3.44%, respectively [31]. 
 
Table 2: Portugal market growth on clinical trials among the top 50 countries (2007-2011). 
Reproduced from source [31].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If we analyze the top 50 by market share in 2011, Portugal rose from 44th to 39th with a 
market share of 0.44% [31]. 
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These results reflect the R&D investment. Countries with a strong tradition in R&D 
investment are the ones that have a big share of GNP (Gross National Product) percentage 
given to R&D investment and are the ones with higher market growth and market share. 
Portugal is in the other group of countries with the lower investment in R&D [31].  
As a consequence of the lower investment in R&D, the number of clinical trials submitted in 
Portugal during the period between 2006 and 2009 is lower than the number submitted in 
other countries like Belgium, as can be easily appreciated in Figure 15 [7].  
 
 
Figure 15: Number of clinical trials in Europe (2006-2009). Reproduced from source [7].  
 
By 2010, the trend was the same and Portugal appears between the countries with the lower 
rate of clinical trials per million inhabitants. As represented in Figure 16, in 2010 Portugal has 
the lower ratio of clinical trials per million inhabitants. 
 
 
Figure 16: Clinical trials in Europe (2010). Representative graphic of the number of clinical trials 
authorized, per phase, and the ratio per million inhabitants, in 2010. Portugal appears between the countries 
with the lower rate of clinical trials per million inhabitants. Adapted from source [8].  
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Along with a low number of clinical trials, comes lower investment from sponsors. Table 3 
compares the active clinical trials, number of sites, number of patients and the total 
investment in Portugal, Austria, Belgium and Czech Republic. Comparing Portugal with these 
similar countries, in terms of number of inhabitants, the difference of investment is evident. 
Belgium captures approximately more €136 millions than Portugal and Czech Republic more 
€173 millions [7].  
 
Table 3: Active clinical trials (2009). Number of active clinical trials and its investment in 2009. Adapted 
from source [7].  
Countries Active Clinical Trials 
Number of Sites 
(Planned) 
Number of Patients 
(Planned) 
Investment 
(Million €) 
Portugal 147 461 3917 58.755 
Austria 188 596 6502 97.530 
Belgium 328 1024 12996 194.940 
Czech Republic 218 967 15433 231.495 
 
This difference of investment is a consequence of the different number of planned patients, 
which is the lowers in Portugal. Figure 17 and Figure 18 can help to better understand the 
situation of Portugal. The number of participants in clinical trials and the number of clinical 
trials and patients per site is low in Portugal, reflecting the difficulty to recruit patients for 
clinical trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Patients per clinical trial in Europe (2005-2008). Adapted from source [5].  
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Portugal has fewer patients per clinical trial and fewer patients per site than Belgium, Austria 
and Czech Republic. 
Portugal has also a reduced number of CT per sites, clearly below that of other Western 
European countries. As a consequence, the number of patients included in clinical trials per 
site is lower. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: CT and patients per site in Europe (2005-2008). Adapted from source [5].  
 
Another difference between Portugal and other countries is the ratio between clinical trials 
promoted by pharmaceutical industry and by the investigator initiative. Countries like Spain 
and United Kingdom have a high number of “academic trials” that represents even ¼ of 
whole clinical trials, in 2010 [8].  
 
 
 
 
 
 
 
 
Figure 19: Proportion of CT by type of sponsor (2010). (%) Adapted from source [8].  
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There are more factors that can be compared in order to frame the main differences 
between Portugal and some European countries with similar population and to identify the 
major reasons that make them more attractive than Portugal in clinical research.  
 
Table 4: Variation factors between Portugal and similar countries. Adapted from source [8].  
 
Countries Portugal Austria Belgium Czech Republic 
Time to regulatory 
approval. (days) 60 35 15-28 60 
Policy and Strategy  
- Organization dedicated 
exclusively to clinical 
research. 
- Financing funds to 
research. 
- One non-profit cluster 
that interacts with 
various stakeholders 
promoting a favourable 
environment to clinical 
trials (Healthcare 
Belgium). 
- Funding and 
incentives for research 
projects of academic 
initiative. 
Regulation and 
Legislation 
- Templates for some 
documents such as informed 
consent (in PNEC).  
- Bureaucracy and non 
standardized procedures 
with many variations 
depending on the 
institutions. The obligation of 
the approval by CNPD. 
- Models of informed 
consent and guidelines in 
order to get 
standardization. 
- Clear guidelines and 
standardization to 
increase transparency.  
- More uniformity to 
reduce administrative 
burdens for companies. 
 
Organization and 
infrastructure 
- Lacks in the quality of 
infrastructures mainly for 
phase 1 (that require 
internment).  
- Centres of excellence, 
groups of clinical 
research and groups to 
help patients. 
- Qualified centres 
dedicated to clinical 
research. 
- Centres of 
excellence specialized 
in therapeutic areas. 
Technology and 
Information 
- One platform to submit the 
amendments and changes in 
study authorization and 
follows the status of the 
request. Clear instructions 
for companies, electronic 
submission of documents 
and monitoring of the status 
of the request.  
- One platform that 
helps and facilitates the 
recruitment and the 
divulgation of clinical 
trials. 
- One platform between 
industry and patients to 
helps in the access to 
information. 
- Provision of 
information on clinical 
trials in internet. 
- Implementation of 
system “one stop 
shop” that centralized 
the submission of 
clinical trial. 
Incentives, Training 
and Career 
- No valuing the research 
career. 
- Few people are exclusively 
dedicated to clinical trials 
and clinical research.  
- Training programs and 
certification of 
investigators. 
 - Fair remuneration to 
the investigators. 
 
 
Table 5 and Figure 20 give a global vision of the number of clinical trials carried out in 
Portugal and in other countries of Europe, from 2010 until the first semester of 2013. 
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Table 5: Number of CT approved in Europe (2010-2012), registered at clinicaltrials.gov. 
Adapted from source [30].  
 Portugal Spain French Belgium Austria Czech 
Republic 
Germany United 
Kingdom 
 
2010 100 689 1200 582 346 288 1385 1032  
2011 87 778 1244 578 360 299 1434 988  
2012 114 757 1290 540 320 253 1244 1060  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Number of CT in Europe (1st semester 2013). Reproduced from source [30]. 
 
If the Portuguese trend continues in the 2nd semester of 2013 we will have, in the end of 
2013, a very low CT number, approximately 70 CT, being 2013 the year with lower number 
of CT approved, since 2006. 
The decline in the number of clinical trials has had a great impact in all stakeholders and 
brings large losses for Portugal. We should emphasize the loss of jobs, expertise personnel, 
innovation and budget, the closure of local clinical operations departments of pharmaceutical 
companies and of research sites, fewer publications and decreased access to innovative 
treatments [6]. 
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III.III. Portuguese Overview 
 
Since INFARMED is the authority responsible for the approval and the authorization of 
clinical trials, it should be interesting to analyze its available data since 2006 to 2012, in order 
to understand the trend on the number of clinical trials submitted and approved in Portugal 
(Figure 21). 
  
Figure 21: Clinical trials applications submitted and approved by INFARMED (2006-2012). 
Reproduced from source [32]. 
 
As show in Figure 22, it is on late development (phase III) that more investment appears.  
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Clinical development phase (2006-2012). Number of submitted and valid clinical trials of 
each phase, between 2006 and 2012. In every year it is on phase III that more investment appears.  Reproduced 
from source [32]. 
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The analysis by type of medicines (tested in Portugal since 2006) shows that chemistry origin 
is still the most studied and the percentage of biotechnological ones has not changed 
significantly (Figure 23 and Table 10) [32].  
 
 
 
 
 
 
 
 
 
 
Figure 23: Type of the active substances tested in CT performed in Portugal (2006-2012). 
Reproduced from source [32]. 
 
It is also interesting, after knowing how many clinical trials were performed and of which 
phases and origin they come from, to understand who are the big investors in clinical 
research. Figure 24 represents the two type of sponsors that have been coexisting in 
Portugal: Pharmaceutical Industry and Academical Researchers. However, the number of 
investigator-driven clinical trials has been much smaller than the clinical trials sponsored by 
the Industry (95% versus 5%- Table 11) [32].  
Figure 24: Number of study applications submitted to INFARMED by type of sponsor (2006-
2012). Reproduced from source [32]. 
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INFARMED shared information of the number of requests for substantial amendments of 
clinical trials approved and the average time to evaluate these changes. There has been an 
improvement in the number of days necessary to answer the request and a significant 
increase on the number of answers that have been given on the established time. Since 2006 
this number increased from 60% in 2006 to 99% in 2012 (Figure 25 and Table 12) [32]. 
 
Figure 25: Substantial amendments notified for authorization (2006-2012). Number of submitted, 
authorized and rejected requests for substantial changes of approved clinical trials, between 2006 and 2012, 
and average time of decision in the same period. Reproduced from source [32]. 
 
 
Once clinical trials are also submitted to approval by CEIC, CEIC data for the same period 
(2006 to 2012) were analysed. 
Figure 26 displays the number of notifications submitted, favourable and unfavourable 
opinions, notifications invalidates administratively and the average time for decision. 
As expected, the number of requests for CT approval by CEIC follows the same trend of 
the number of CT applications to INFARMED. We could verify a decrease in number from 
2006 to 2011. Only in 2008 and 2012 can be seen a slight increase. The average time for the 
transmission of the CEIC opinion and approval also decreased, since 2007. In 2007 was 66.9 
days and in 2012 was 42.3 days [33]. 
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Figure 26: Requests for approval of clinical trials to CEIC (2006-2012). Number of requests 
invalidated administratively, number of favourable and unfavourable opinions and average time of decision, in 
the same period. Adapted from source [33]. 
 
Regarding requests for opinion, to perform substantial CT amendments, Figure 27 shows an 
increase of the requests. This follows the same trend of INFARMED’s numbers. Related to 
the average time to answer the request there has been a decrease in the number of days 
that was very significant for CEIC. In 2006 CEIC took on average of 74.1 days to respond. In 
2012 CEIC already responded in 31 days.  Despite the same tendency of numbers, between 
CEIC and INFARMED, the CEIC had always a higher number of requests to important 
changes than INFARMED [33]. 
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Figure 27: Requests for approval of substantial clinical trials amendments by CEIC (2006-
2012). Number of requests invalidated administratively, number of favourable and unfavourable opinions and 
average time of decision in the same period.  Adapted from source [33]. 
 
It is important to note that the approval time by CEIC is also affected by the time that 
sponsor takes to answer to the questions and doubts of CEIC. When CEIC requires 
additional information from sponsors, they have to study and formulate their answer and 
this take some time. After that, CEIC has to review the answers. As can be seen in Table 6, 
sometimes sponsors take a long time to answer. 
 
Table 6:  Average time of sponsors answers to the request for additional information by 
CEIC (2011-2012). Time 0.0 means that the answers were given in one day.  Adapted from source [33]. 
 
Answers to 
Additional 
Information 
To Perform CT  
(days) 
Perform Substantial CT 
Amendments 
(days) 
Average 
response time Minimum Maximum 
Average 
response time Minimum Maximum 
2011 24.0 1.0 128.0 31.0 1.0 173.0 
2012 21.6 0.0 238.0 28.1 1.0 102.0 
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In Portugal, CNPD must also give the authorization to the clinical trial and the data 
treatment. Table 7 displays the number of authorized clinical trials by CNPD.  
It wasn’t possible to access the number of notifications submitted. However, in general, all 
requests are accepted by CNPD. Sometimes what can occur is a partial authorization. In 
these cases CNPD doesn’t accept the treatment of some data, like racial data, and asks to 
change the protocol [34].  
CNPD numbers are different from the notifications submitted to INFARMED and CEIC. 
Generally the notifications authorized by CNPD are fewer than INFARMED and CEIC. 
Despite this difference, the trend is similar. The difference is only noticed in 2011 where 
CNPD had a slight increase of notifications in contrast to INFARMED and CEIC decrease. 
 
Table 7:  Requests to perform clinical trials to CNPD (2006-2012). Adapted from source [34]. 
 
CNPD 2006 2007 2008 2009 2010 2011 2012 
Notifications Authorized (N) 36 91 169 119 98 109 139 
 
Related to average time for the authorization to treat clinical trial data, CNPD hasn’t got 
these data available per year. So, it isn’t possible to evaluate the variation and if there has 
been a decrease in time. However, during my conversation, it was possible to identify that 
the time for approval varies with the complexity of the clinical trial and also with the 
necessity of CNPD to require more information or request changes. In this case, the time 
that sponsors take to answer also has influence in the CNPD authorization time [34]. 
Despite these variations, generally, CNPD takes in average two months to respond [34].    
In Figure 28, the average time between the submission of the request to initial approval and 
the reception of the consent from the last regulatory entity can be seen, time that exclude 
the average time of approval by the administrations board of clinical trial sites [8]. 
 
 
 
 
 
 
Figure 28: Time of approval by all regulatory authorities, in Portugal (2009-2012). The average 
time (days) between the submission of the request to initial approval and the reception of the consent from the 
last regulatory entity, in Portugal. In these numbers are excluded CT whose approval is pending and the 
average time of approval by the administrations boards of clinical trial sites. Reproduced from source [8].  
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The previous graphic only considers the average time since the submission of the request to 
the reception of the consent from the last regulatory entity. If the whole approval process 
was considered, taking into account also the approval time by sites, the real time of clinical 
trial approval, in Portugal, is higher than 6 months [8]. 
 
It is also important to analyze the investment in clinical trials in Portugal. APIFARMA studied 
the potential of investment wasted in Portugal. An analysis of 443 clinical trials, conducted 
from 2007 to 2011, compared how much money was planned to be invested in Portugal 
versus the money that was actually invested (Table 8) [7]. 
 
Table 8: Planned versus real investment (2007-2011). Total of planed investment versus the actually 
investment in 443 clinical trials conducted in Portugal between 2007 and 2011. Adapted from source [7].  
 
For areas like Cardiology and Neurology, the actual investment was approximately 50% of 
the planned investment. Globally, from 2007 to 2011, Portugal lost approximately €14 
millions of the planned investment. The number of non-included patients was 1191, which 
corresponds to 32.4% of the planned number of patients. Portugal only included 70% of 
patients initially planned [7]. 
This is a consequence of a decrease on the number of new patients recruited for CT that 
have been noticed, with an exception for the year 2011 (Figure 29) [8]. 
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Figure 29: New patients recruited in Portugal (2009-2012). With exception for the year 2011, 
between 2009 and 2012, the recruitment of new patients has been decreased. In 2012 only 936 new patients 
were recruited. Reproduced from source [8]. 
 
The total investment in 2012, in Portugal, was €36 millions that correspond to €3.6 per 
capita. In EU, the investment was €20,000 millions. This corresponds to €40 per capita. If 
Portugal would be in the EU average the investment would be about €400 millions instead of 
€36 millions [29]. 
The economic value of clinical trials has a very relevant impact on Portuguese economy. In 
2012 the market value was €36 millions, with a direct gross value added of €21 millions and 
€7.5 millions of tax revenues. The value of exports resulting from the clinical trials rose to 
€33 millions, which contributed for less public spending, saving €3.5 millions to the State and 
we also had, in 2012, 1086 jobs dedicated to clinical trials. The global impact on Portuguese 
economy can be evaluated using GNP multipliers. For the clinical trials area, this multiplier is 
€1.98, which means that every €1 investment generated in clinical trials activity provides a 
return of €1.98 for the general Portuguese economy. This puts clinical trials on the top 10 
for the activities with better return (Figure 30)[8]. 
Multiplying the factor of multiplication for clinical trials with the market value of this activity 
we obtain the total impact of clinical trials in Portuguese economy, which was €71 millions in 
2012 [8]. 
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Figure 30: GNP multipliers. GNP multipliers for each Portuguese activity sector. For the clinical trials 
area, this multiplier is €1.98, which means that every €1 investment generated in clinical trials activity provides 
a return of €1.98 for the general Portuguese economy. Adapted from source [8]. 
 
Another issue that can be interesting to analyse is the distribution of clinical trials per site 
and per sponsor, in Portugal.  
Analysing the CT per sites in Table 9, we observe that 30% of the clinical trials conducted in 
Portugal are concentrated in two big sites. Between 2006 and 2011, from 22 centres that 
performed more than 10 clinical trials, only 6 are responsible for performing 609 clinical 
trials of the 943 (the total number of CT considered for this period), that corresponds to 
approximately 65% [35]. The clinical trials performed in primary health care units are greatly 
reduced [8]. 
 
Table 9: Table of the distribution of clinical trials per site (2006-2011). (It was considering only 
sites that performed more than 10 clinical trials). Adapted from source [35]. 
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Analysing the most recent data about the distribution of CT per Portuguese localities 
(research carried out on web sites www.centerwatch.com, clinicaltrials.gov and 
clinicaltrialsregister.eu., in 13 August 2013, by Pedro Silva) it can be verified that there is a 
concentration of CT in Oporto, Lisbon, Coimbra and Almada. As shown Figure 31, all other 
localities are performing, each one, less than 10 CT and the majority only one or two [36]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Number of CT by Portuguese locality (August 2013). Graphic representation of the 
distribution of CT per different localities of Portugal.  There is a concentration of CT in Oporto, Lisbon, 
Coimbra and Almada. All other localities only are performing, each one, less than 10 CT and the majority only 
one or two. These data were updated at 19 August 2013. Adapted from source [36]. 
 
The distribution of CT per sponsor can be analysed in Figure 32. In 2012, Portugal had 41% 
of the whole active CT provided by only 3 companies and 59% of the number of recruited 
patients concentrated in the same 3 companies [8].  
 
 
 
 
 
 
Figure 32: Clinical trials concentration on top 3 companies (2009-2012). Concentration of clinical 
trials and patients on the top 3 companies, between 2009 and 2012. In 2012, we had 41% of the whole active 
clinical trials in Portugal provided by only 3 companies and if we analyze the number of patients recruited, the 
concentration is even higher reaching 59%. Adapted from source [8]. 
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The top sponsors who had the most clinical trials approved by INFARMED in 2012 are: 
Merck Sharp & Dohme Corp., Janssen-Cilag International NV, Novartis Pharma AG, 
Boehring Ingelheim, F. Hoffmann-La Roche Ltd., Astellas Pharma Europe B.V., Amgen Inc. 
and GlaxoSmithKline Research and Development Limited. They are all international 
companies [32]. 
Figure 33 shows the sponsors of CT that are being currently perform in Portugal (research 
carried out on web sites www.centerwatch.com, clinicaltrials.gov and clinicaltrialsregister.eu., 
in 13 August 2013, by Pedro Silva) [36]. 
 
 
 
Figure 33: Clinical trials by sponsor (August 2013). Graphic representation of the distribution of CT 
per sponsors.  The sponsor who performed more CT in Portugal is Hoffmann- La Roche with 10 CT. These 
data were updated at 19 August 2013. Adapted from source [36]. 
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IV. Critical Factors, Perspectives and Challenges of Clinical Trials in Portugal 
IV.I. Critical Factors for Portuguese Clinical Trials 
 
Bureaucracy 
 
The Directive 2001/20/EC is considered by many voices as one of the causes for the 
decrease of the number of clinical trials in Europe (25% from 2007 to 2011) and, 
consequently, in Portugal [37]. 
In spite of the fact that this Directive has brought important improvements related with 
participants safety and ethics, it should be the legislative act of the EU most criticized in the 
field of pharmaceutical products, by all sectors involved (investigators, industry and 
participants). The main reason is being a Directive whose transposition for national 
legislation varied from country to country because the obligation is related to the final result 
and every country is free to adopt the most appropriate methods to achieve that [38]. 
The result was an unfavourable regulatory framework for clinical research with direct effects 
on the costs and feasibility of clinical trials. The consequences were an increase on the costs 
of clinical trials (the necessary human resources increased a lot, as have the administrative 
requirements, mainly for non industry sponsors-97%) and an increase of the mean period 
until the beginning of the clinical trial (in 90%), which reached 152 days. This directive 
brought an excessive administrative and bureaucratic burden and it does not differentiate the 
sponsor and the different risk of the different phases of the clinical trial [38]. 
In order to modify this situation there is a new legislation proposed by the European 
Commission that will take the form of a Regulation. A Regulation doesn’t need transposition 
and is direct and globally applied in all member states without the involvement of national 
authorities. This ensures harmonized and standardized procedures and it will propose:  
- An authorisation procedure for clinical trials which will allow a fast and through 
assessment of the application by all MS [37]; 
- Simplified reporting procedures in order to spare investigators from submitting 
identical information to various bodies and MS [37]; 
- More transparency on recruitment participation [37]; 
- Clear deadlines and a principle of tacit approval to ensure compliance [38]; 
- Each MS is responsible for defining the organizational structure and internal skills for 
the evaluation of each authorization request for clinical trials [38]; 
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- Eliminates the requirement imposed by Directive 2001/20/EC related to the 
existence of the insurance/ compensation for clinical trials where there is no 
additional risk or when the risk is negligible, in order to reduce costs and 
administrative burden. (The requirement of this insurance worsened the costs and 
administrative burden of performing clinical trials by non-commercial sponsors, which 
have great difficulty in obtaining this coverage) [38]; 
- The implementation of controls by the European Commission, in MS and other 
countries, to make sure the rules are being properly supervised and enforced [37]. 
With this regulation, a more identical application of the legislation will be obtained, reducing 
the differences between countries. This proposal has been discussed in the European 
Parliament and it is expected to come into effect in 2016 [37].  
 
In addition to this problem, that is transversal to every MS, Portugal has other bureaucratic 
problems that make its situation more unfavourable than the other MS.  
- Double ethical evaluation. 
When directive 2001/20/EC was transposed in Portugal, CEIC was created. As referred in 
Chapter II, the objective of this creation was to standardize the ethics and makes this 
authorization independent of the existence of ethics committees in the clinical trials centres. 
However, even though only one opinion is required by law (opinion by CEIC or Opinion by 
any CEC designated by CEIC) in Portugal, what usually happens is that the clinical trials sites 
do not approve the trial without the favourable opinion of their own ethics committee. So, a 
kind of double ethical evaluation is created, delaying the trial start. The process takes longer 
when the opinion of different CES is totally different. 
- Approval by CNPD. 
The Directive 2001/20/EC doesn’t require the approval of trials by commissions related with 
data protection. However, Portuguese legislation created the CNPD that has to be notified 
by the sponsor and has to give permission to start the clinical trial [23]. To complicate the 
situation this commission hasn’t experts specializing in health area and there isn’t a deadline 
on the CNPD approval. As more agents have to give permission to the sponsor, more 
complexity in the approval process and more delays occur for the start of clinical trial. It is 
important to review the role of CNPD. A guideline should be created and would be 
approved by CNPD of which obeyed the treatment of data and that shouldn’t require the 
approval of CNPD, or alternatively, defining, at least, deadlines for the approval of CNPD 
[8].   
 
57 
- Specific legal framework for disclosure of clinical trials. 
In Portugal there aren’t specific laws for the divulgation of clinical trials and it is applied the 
legal framework for medicines [8]. On “Statute of Medicines” can be found the regulation for 
public advertising and advertising for health care professionals. The rules for advertising 
medicines that need medical prescription are very restrictive. The advertising for this type of 
medicines is limited to health care professionals, through technical publications, and never be 
accessible to the public [39]. There is a pressing need to provide specific legislation to clinical 
trials in order to avoid lack of knowledge about ongoing clinical trials and consequently 
increase the recruitment potential.  
 
These problems along with the approval times by various entities are responsible for delays 
in the beginning of clinical trials. However, analyzing Figure 34, it is possible to verify that on 
the top 3 are causes whose responsibility belongs to the sponsors and the centres and not 
to the authorities and legislations. The negotiations between sponsors and centres, the 
patient recruitment, drug availability and the protocol design are the main causes for the 
delay that are listed by Professors Luis Almeida and whose solution will certainly improve 
clinical research [27]. 
 
 
 
Figure 34: Causes of clinical trials delays. Representative graphic of the causes of clinical trials delays. 
Reproduced from source [40]. 
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Sponsors and Sites  
 
- The quality of the protocol. 
Protocol design, its correct interpretation and the necessary amendments are appointed as 
causes for delays and have a very high impact. Pressures on R&D spending and the necessity 
to obtain faster results are the reasons for the growing tendency to submit protocols that 
aren’t fully mature yet and that, consequently, require more amendments throughout the 
approval process. These can be visualized on Figures 25 and 27 where we observe a strong 
increase on the number of amendments in the last seven years (from 64 amendments in 
2006 to 332 in 2012) [6]. It is very important to improve the quality of protocols to reduce 
amendments and the waste of time and also to allow a correct interpretation of the 
protocol with consequences, for example, on the improvement of recruitment.  
In addition, the requests for clarification and amendments are frequently send in the end of 
the legal time to be approved and normally are inconsistent, systematically changing the legal 
deadline [8]. 
- Difficulties in negotiation the Financial Contract. 
This document states the financial terms and other details between the sponsor and the 
clinical trial sites and, after a consensus is achieved by both parties, still needs to be 
approved by CEIC. In Portugal, the time for this negotiation is very long. This is an 
administrative factor that needs to be improved, in the best interest of both, the sponsors 
and the sites. The result will be a reduced time for initiation a clinical trial [27]. It is 
important to refer that there isn’t a legal deadline for this approval and that is may take 
several months [8].  
- Lack of procedures and harmonized politics related to clinical research. 
Added to the long time that hospital administrations take to analyze and review the 
contracts (which most of the times only begins after the approval of CEIC and INFARMED) 
we have the lack of clear politics and harmonized procedures, resulting in an extended time 
for CT approval [41]. 
- Failure response time to the Feasibility Questionnaire. 
The FQ is sent for several sites in many countries by the sponsor. These FQ will provide the 
sponsor the necessary elements it needs to evaluate which site or sites are best to perform 
his clinical trial. The timeliness of the sites’ answer is very important and demonstrative of 
the interest and motivation to participate in that clinical trial. However, in Portugal, there 
are many sites that do not comply within the intended timeframe. This is very negative both 
for the reputation of the site as even for the Portuguese itself reputation because our 
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country becomes connoted to the idea of failure, not compliance and lack of interest. This 
negative situation is an important reason why, sometimes, the sponsors do not contact 
Portuguese sites for conducting clinical trials. Meeting deadlines becomes more important 
when sites are contacted by CROs that also have deadlines to meet with the sponsor [42]. 
- Unrealistic answers to Feasibility Questionnaire. 
Another problem related to FQ is the common unrealistic answers provide by the sites. This 
occurs because sites, with the objective of attracting more clinical trials, provide unrealistic 
answers to FQ, namely the number of patients that can be recruited. The result is that the 
site is chosen by the sponsor based on the FQ answers but when the clinical trial actually 
begins, the site cannot meet the expectations and may jeopardize the clinical trial. This 
removes credibility to the centre and explains the big difference between the numbers of 
planned patients versus patients really included. This is also a reason for sponsors and CROs 
to lose confidence in Portuguese sites [42]. 
- Failure time to the recruitment. 
The recruitment phase is the period during which sites can include patients in the clinical 
trial. Also because of unrealistic answers to FQ, many sites in Portugal don’t have the 
capacity to include the planned patients during the recruitment time given by the sponsor 
and also take a long time to include the first patient. In Portugal, the amount of time elapsed 
between the proposal to perform the clinical trial, and the recruitment of the first 
participant, is, on average, one year. This is very disadvantageous mainly in competitive 
clinical trials where the period for recruitment is over as soon as the intended number of 
participants is achieved, independently of the sites of inclusion. One clinical trial that needs 
to include 100 participants within three sites: a Portuguese site, that planned to include 20 
participants, a Spanish site that planned to include 30 participants and a French site that 
planned to include 50 participants. If it is a competitive clinical trial and, at the end of the 
first month of the recruitment, the French site has included 73 patients, the Spanish site has 
included 25 and the Portuguese site has included 2, the recruitment phase will be finished. 
So, the Portuguese site, that could have included 20 participants, only included 2. This 
example is the reality in Portugal [42].  
- Lack of research sites of excellence. 
Portugal has some good research centres but there is a gap related to the necessity of 
hospitalization and more specialized equipment, as for phase I [42]. The creation of 
specialized sites is very important, with a clinical trial management team, experienced 
physicians in clinical trials and proper standardized operating procedures [41].  
 
 
 
60 
- Lack of cooperation for clinical research. 
In Portugal there is an inefficient share of knowledge and CT are performing autonomously 
by each sponsor or each researcher [8].  
- Top 8 of sponsors are constituted only by international companies. 
A significant slice of clinical trials performed in Portugal is sponsored by international 
companies. For these companies, the major reason to invest is a globally favourable 
environment in clinical research. If the environment isn’t the best, they can easily transfer 
the clinical trials to other countries [8]. 
- There are few clinical trials performed in primary health care units. 
This is a result of the law restrictions related to conditions, infrastructures and support 
researchers for performing a clinical trial. 
It is important to implement the creation of conditions to perform clinical trials in these 
sites: cooperation mechanisms with sites, partnerships with community pharmacies to 
control the experimental drug circuit and medical emergency protocols with local hospitals 
[8]. 
- There are few investigators initiated trials. 
The conditions to promote independent clinical research are limited in Portugal. There are 
few investigators with fund, support, partnerships and enough qualified support structures to 
perform a clinical trial. It is important to review the legislation, in order to facilitate the 
sponsorship to investigators, for example by eliminating or decreasing taxes, reducing 
administrative complexity and costs and supporting the submission of clinical trials. For 
example, in Spain the exemption of taxes for the projects performed by independent 
investigator has been already enacted [8]. 
 
Therefore, to solve these problems it is imperative to improve the flexibility in the 
negotiations between sponsors, CROs and sites. It should be certainly useful the existence 
of a financial contract model that could regulate the negotiations even between different 
sites. It is also crucial that the site has a timely and realistic answer to the FQ. The 
cooperation among all stakeholders is of utmost important. We have to take as example the 
African Proverb “If you want to go fast, go alone; if you want to go far, go together”.    
 
Human Resources 
 
Another obstacle to the realization of clinical trials is the technical human resources available 
in Portugal. We have very good healthcare professionals but whose training hasn’t had the 
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clinical research as priority. It is fundamental to reinforce the training of the healthcare 
professionals (introduce mandatory subjects on research during the degrees and post 
degrees, recognize and value the clinical research careers [41]) in order to target and 
differentiate human resources for research. It is also fundamental to support research teams, 
involve healthcare professionals in innovative projects, encourage, support and recognize the 
clinical research career in order to ensure that healthcare professionals consider the clinical 
research an important activity. Clinical research certifications can be created as well as 
cooperation between academic institutions, healthcare units, healthcare companies and 
regulatory authorities in order to improve the development of healthcare professional’s 
competencies and recognition of their qualifications [8].  
Another problem is that, for the majority of healthcare professionals, the research activity is 
perceived as add-on tasks, specially the assistance activity, because we have a lot of hospitals 
without specific human resources affected to the clinical trials [41]. This results in a lack of 
motivation of the professionals principally because the clinical research requires a lot of time 
(it is necessary to register a lot of information about the patient, the patient requires a lot of 
care and a lot of administrative requirements [43]) and dedication by everyone involved [42]. 
It is important to enable them with the possibility of choosing the area of work: clinic or 
research. The full-time dedication to clinical research is fundamental. With this specialization 
we will find more efficacy, dedication, motivation and positive results. The team responsible 
for conducting CT should be constituted by different types of professionals such as 
physicians, nurses, pharmacists and study coordinators. In order to guarantee a smooth 
conduction of the CT everyone’s role must be well documented. 
 
Patient Recruitment 
 
Patient recruitment and retention is of utmost importance because it contributes to 
determine whether clinical studies comply with the timelines.    
One cause for the poor recruitment rates in Portugal can be the lack of divulgation and 
information of the clinical trial to the patients. In Portugal the main stream and almost only 
source of recruitment is through the own medical practice of the researcher and medical 
references from professional colleagues [42]. However, there are many other sources that 
aren’t used in Portugal, because of the legislation restrictions, but are used in other 
countries like [43]: 
- Government employees (e.g. military); 
- Private industry (e.g. clinics in large industries);  
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- Referrals from clinical laboratories; 
- Mass media strategies (via newspaper or radio advertisements); 
- Mass mailings; 
- Community screening; 
- Participants in other clinical studies; 
- Blood banks (blood donors); 
- Local advertisements (notices on bulletin boards); 
- Site Specific Database; 
- Other sources (see chapter of V). 
These sources are very important for the advertising of a clinical trial and for the increase of 
eligible patients for the study. If Portugal wants to achieve the recruitment rate levels from 
other countries, will need, urgently, to develop specific legislation for advertising clinical 
trials. However, this is only the first step. After that it is still necessary to carry out an 
important amount of work through information and awareness of the patient to participate 
in the study. This is important because many of those who were aware of the clinical trial 
option refused to participate because a lot of factors such as a possible of ineffective new 
treatment, getting in the placebo arm and out-of-pocket expenses [10]. It is very important 
to change these ideas and transmit to the patient all information about the clinical trial, with 
an appropriate language so that he can understand, mention the potential benefits of their 
participation and essentially giving him confidence without pressing the patient. It is also 
important that the patient feels free to ask all the questions and get all the information to 
show to the family and friends [42]. There are several factors that influence patient 
recruitment and that should be taken into account to improve the recruitment, such as [43]: 
- Source of patients referral: medical sources, other clinical studies, clinical 
laboratories, blood banks; 
- Number of patients contacted via letter, telephone, or direct approach using mass 
mailing, mass media, friends, advertisement or other methods; 
- Specific place where mass screening occurs: at workplace, educational facility, social 
group, community location or elsewhere; 
- Socioeconomic composition of the patient pool; 
- Location of the study site relative to patients’ home or work; 
- Degree of concern that patients have for their disease; 
- Nature of patients appeal to enrol in the study; 
- Specific requirements and demands of the study (in terms of difficult or disagreeable 
tests); 
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- Amount of remuneration or other benefits (meals, transportation) given to patients; 
- Hire additional personnel to help recruit patients; 
- Conduct additional medical chart reviews and/or reviews of pharmacy records; 
- Determine what is motivating patients to enter as well as not to enter in the clinical 
trial and attempt to address patients needs; 
- Review hospital admissions or clinic appointments to seek potential patients; 
- Provide a tour of the clinic for prospective patients and answer their questions; 
- Devote more time to recruitment and give it a higher priority in terms of efforts. 
There are also retention strategies like [10]: 
- Dialoguing assistance: intensify communication and intervention; 
- Visit reminders; 
- Compliance reminders: use phone and texting reminders; 
- Educational support; 
- Treat all participants well and give them attention; 
- Ensure feedback is provided sensitively and quickly; 
- Ensure any retribution or compensation are processed swiftly; 
- Understand any signal of lack of interest to combat and prevent retention problems. 
Another important measure to give confidence to participants is the publication of the 
clinical trial results. This is essential, even when the results are not expected ones. For 
patients, is important to know the results and understand that they are always a source of 
development and progress. For other researchers they are essential, at least, to know that 
way isn’t the best way [42]. 
It is urgent to improve the recruitment. To help in the screening of eligible patients it should 
be important the bet in the development of informatics tools for hospitals to introduce all 
the information about all patients, which would greatly facilitate the patient research by 
characteristics needed for clinical trial. If Portugal is a small country with few patients, we 
have to make all efforts to have an efficient recruitment. To improve the advertising of 
clinical trials, an investment in the information and awareness of eligible patients may be the 
solution [42]. Why not invest in awareness by proximity and work this issue in healthcare 
centres and pharmacies? 
We also can take the example of United Kingdom and promote initiatives that involve 
society like the creation of a portal “people in research” where there are news, divulgation 
and the integration of people and patients in groups of work related to clinical research and 
a bet in the specific divulgation, publication and documentation about the benefits of clinical 
trials. Also in this country the legal barriers of disclosure were minimized in order to 
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promote the recruitment. In some material of promotion of clinical trials phase I in UK it is 
even referred the payment to participants. This initiative is also a simplification of law and a 
diminution of bureaucracy [8]. 
In Portugal, the importance of CT divulgation was understood by CEIC. In order to clarify 
and adapt its position having in mind the evolution of society a document was developed 
with some ideas. It was under public discussion until February 2013. In this document it was 
highlighted the necessity of divulgation of CT because it isn’t acceptable that the CT 
information was available only for some patients. However, CEIC clarified the difference 
between divulgation and advertising, refused all type of advertising and restricts the type and 
how information can be transmitted because CEIC didn’t ignore the human-being 
vulnerability in case of disease. Therefore, even though the tendency is to improve the 
divulgation and the information about CT, Portugal is still far from having types of CT 
disclosure similar to other countries [33]. 
 
Other aspects 
 
Funds and financial incentives for clinical research. 
 
The fund provided by the State Budget for laboratories and research has declined. In 2012 it 
was €74.5 millions but this year it is only €65 millions [44]. The financial incentives to clinical 
research aren’t paid on due time or even never paid to sites and researchers. This is very 
discouraging. The review of fiscal incentives is also important as they may be seen as an 
investment incentive and may improve the competitiveness of our country [8].  
For example, in UK, a National Institute for Health Research was created in order to 
manage funds to support investment. In the period between 2012 and 2017 it approved a 
package of 102 million Pounds for the development of 19 Clinical Research Facilities for 
Experimental Medicine [8].  
 
Policy and Strategy 
 
In Portugal there is a lack of recognition of the strategic importance of clinical research for 
the improvement of health care and national economy. The result is the disinvestment and 
the loss of competitiveness. The nonexistence of a strategy for clinical research has resulted 
in maladjustment of the laws that regulate the sector, inefficiency of financing systems, 
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discouragement for the improvement of sites conditions and creations of research networks 
[8]. 
 
Hospital administrations 
 
There is a discomfort of administrators related to clinical trials. Some of them don’t 
recognize the importance of clinical trials for the hospitals and they have their institutions 
focused on clinical practice. So they are reticent about clinical trials because they think about 
the increase of costs with medicines, with human resources and they are unprepared to 
evaluate and approve a clinical trial [8]. 
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IV.II. SWOT Analysis of Clinical Trials in Portugal 
 
 
 
 
 
 
 
Figure 35: SWOT analysis of clinical trials in Portugal. Evaluation of Strengths, Weaknesses, 
Opportunities and Threats involved in clinical trials performed in Portugal. Adapted from sources [23, 26, 27, 
38, 42, 44-47]. 
Strength
- High quality of human resource;
- Strong connection of sites with
Universities and schools;
- High diversity of patologies and
patients;
- PNEC platform;
- Sites with high quality, visibility and
recognition (CHUC,AIBILI and others);
- Motivation to change and to performe
CT;
- New law proposal.
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- Bureaucracy;
- Unfavourable regulatory framework;
- Approval by CNPD;
-Difficulties in negotiations of the
Financial Contract;
- Failure response time to FQ and
unrealistic answers;
- Failure time and difficulties in the
recruitment.
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- Improve recruitment and
concentration of patients;
- Improve networking of sites and
researchers;
- Motivation of government, authorities
and responsibles to reduce bureaucracy
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- Supportive governmental framework;
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- Introduction of "One-Stop-Shop";
- Definition and standardization the CT
costs;
- New paradigm for Clinical Research.
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- High dependency of regulatory
entities;
- Effors to contain healthcare
expenditures;
- Relocation of clinical trials to
emerging markets;
- High level ofTranslational Gap.
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IV.III. Possible Strategic Plan to Promote Clinical Trials in Portugal 
 
Being aware of the main issues related to clinical trials in Portugal, it is urgent to develop a 
strategic plan for the promotion of CT that should complement the possible solutions that 
have been already enumerated along the present dissertation. Success cases as Belgium, 
Czech Republic and Austria should be an example for Portugal that has the duty to know 
and implement the measures followed until now by these countries.  
 
Figure 36: Necessary changes. Changes needed for organizations in order to allocate more clinical trials. 
In top 3 are standardization, networking and transparency in clinical trials costs. Adapted from source [6]. 
 
The main strategies taken by these countries were: improve the local legal framework, 
define clear guidelines and more transparent communications, improve access to patients 
and promote networks of clinical trials centres [6]. 
 
- Networking of specialist expertise centres and healthcare professionals. 
In order to facilitate the pooling and sharing of expertise, best practices and transference of 
key knowledge between centres, it is also important to avoid fragmentation of competencies 
and improve access to patients. An independent organization dedicated exclusively to clinical 
research can be created. Its mission should be the development of clinical research and the 
articulation between all stakeholders [6]. 
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- Evaluation of the introduction of a “One-Stop-Shop” principle. 
To access relevant researchers and hospitals (Denmark), there is an on-line portal for 
submission of trial applications where both the competent authority and ethics committee 
approval processes are centralized. It should also standardize, centralise and harmonise 
processes like ethics committee and competent authorities’ approvals, patient information, 
clinical trial contract agreements, financial negotiation formats and informed consent forms 
made available to applicants through the portal. The portal ought to be linked to a clinical 
trial register indicating which trials are recruiting as well as a patient registry that can assist 
in the localisation of suitable trial participants. This would lower cost and time efforts, while 
improving transparency and access to patients and key information [6]. 
- Develop a Supportive Governmental Framework. 
The main objective is facilitates the access to innovative drugs based on standardization and 
centralisation [6].  
- It is important to ensure the optimization of the regulatory and legal aspects. 
Try to define and implement shorter deadlines for the approvals and also for the validation 
of the submitted documentation that shouldn’t be longer than 24 hours and create guidelines 
to define deadlines for the approval of the financial contract are some examples [8]. 
- Define and standardize the CT costs in order to promote their transparency [6]. 
- Improve the recruitment, implementing strategies like those already listed.  
Create a work group focused only on the recruitment (like in France whose objective was 
“recruit much, much, faster and better.”) and whose key actions include promoting clinical 
research, harmonise procedures to shorten the set-up time of clinical trials, provide human 
resources to support researchers and support a national network of clinical trials, clinical 
trials sites, healthcare professionals and patients [6]. 
- Provide training and education to clinical trial centres and their staff.  
It is important to share best practices, standardise trainings, develop mechanisms for 
accreditation and raise the level of clinical trials know-how in order to strengthen their 
competitive reputation of quality and expertise [6]. 
- Provide training and education to competent authorities and ethics committees. 
The objective is ensuring training in relevant multi-disciplinary expertise in order to raise the 
bar in terms of approval times and their processes [6].  
- Provide training and education to researchers, patient organisations and patients. 
It will increase the motivation to participate in clinical research projects and in CT [6]. 
- Provide training and education to whole community. 
It will highlight the vital importance of the CT in Portugal [6]. 
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So, the strategic plan can be summarised into 3 key steps: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Strategic plan. 3 Key strategic initiatives to promote clinical trials. Adapted from source [6]. 
 
 
Without the implementation of any strategies or measures that could minimize the actual 
hurdles to clinical research and clinical trials, it is estimated that the future evolution is the 
same of occurred between 2009 and 2012 and will be a negative impact of 4% on the volume 
of clinical trials [8]. 
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V. The Role of the Pharmacist 
 
The pharmacist is a health professional whose intervention during a clinical trial is very 
important. The broad training of a pharmacist enables this professional to give an enormous 
contribution to clinical research and clinical trials.  
The pharmacist is present since the beginning of the development of the new medicine when 
we have this professional in a laboratory working in R&D and applying its knowledge about 
chemistry and pharmacology. In the Galenical & Analytical development laboratory we can 
also find pharmacists doing a great job.   
After that, the pharmacist is also present in the production of the experimental medicine 
where the objective is to make a medicine complies with every specification with high 
standards of quality. 
Related to the performance of a clinical trial, it is possible to find pharmacists as members of 
INFARMED, CEIC and CECs with a relevant role in the analyses of clinical trials and with 
influence in their approval. 
When the clinical trial is approved, we have pharmacists working in the elaboration of all 
clinical trial documentation and with the responsibility of organizing the Quality Management 
System (QMS). In all levels of organization of quality activities we can have a pharmacist even 
to perform the tasks of Quality Assurance Officer.   
Closer to the medicine, we have the pharmacists that are responsible for the experimental 
medicine at sites and consequently for its storage, control and dispense. For that, the 
pharmacist has to establish rules and procedures whose compliance is mandatory and are 
the guarantee of the good management, handling, conservation and administration of the 
experimental medicine to the patients. Related to this task, the pharmacist has the obligation 
to make all recommendations related to the administration of the medicine (about doses, 
frequency and time) and also inform the patient about possible adverse reactions and 
possible interactions, with other medicines or even food and drinks [48]. 
However, I think that society and particularly clinical research have to take more advantage 
from this professional, from his/her skills and from its proximity with all population. I am 
talking particularly about pharmacists who work in community pharmacies. This healthcare 
professional is very competent and has two real characteristics that can improve the 
performance of clinical trials. The first is the very good distribution and proximity to the 
population especially to patient population (in many cases is the unique contact of healthcare 
professionals with some patients) and the other is that the majority of the population 
recognizes the competence of this professional, which is very important to transmit credible 
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information and to educate and enlighten the population. We have a great opportunity to 
use the pharmacy channel to transmit information about clinical trials and to inform people 
about the advantages of clinical trials for population. With this, we can organize informative 
campaigns about the real objectives of clinical trials and try to finish with the idea that 
participants are “guinea pigs”. Pharmacists can also advertise specific clinical trials and help in 
the recruitment, directing eligible patients for clinical trials centres. 
Another participation of the pharmacist and pharmacies can be the support to the idea of 
the realization of more clinical trials in units of primary health care. For this to be possible, 
we have to guaranty that the experimental medicine is transported and available in these 
sites under controlled conditions and on time. With Portuguese pharmacies network and 
the ethical and professionalism of pharmacists, we can control the circuit of the 
experimental medicine [8].     
In the end, we have another important contribution of the pharmacist, the collaboration in 
educational programs by the organization of meetings, debates, conferences an even 
university courses, masters and post-graduations of awareness and specialization in clinical 
research [48]. 
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Final Conclusions 
 
In 12 June 2013 a minister said that clinical research was a fundamental area for a continuous 
quality improvement, it was a way to have access to innovative treatments, encourage the 
creation of centres of excellence, improve the knowledge and project Portugal to the first 
line of technological development. It is a good signal when clinical research and its 
importance are recognized in the Portuguese Parliament and by our governments. It is a 
good signal when they recognize the role of authorities in providing conditions for the 
development of good and qualified clinical research and set priorities when these priorities 
serve as guidelines and haven’t got a limiting role. It is a good signal when they recognize the 
imperative necessity of health care professional’s motivation, of theirs formation and of the 
revision of their contracts [49]. It is a good signal so that the society can understand the 
importance of clinical trials [29]. 
As many voices said, it would be a sign of culture and modernity, if the government and 
hospital administrators admitted the catalytic role of clinical research and considered it as an 
investment. Maybe that time has come. 
Some people are beginning to invest in human resources of quality, technical capacity and 
innovation, so clinical research and clinical trials may turn out to be one of the major 
competitive areas in Portugal [29]. 
There is still a long way to go since we have less than 10% of the potential that clinical trials 
can generate. However, the current situation can be a positive factor because it predisposes 
to change and if the interests of all stakeholders are assured, the future of clinical research in 
Portugal will be guaranteed [29]. 
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Appendix 
 
I-Tables from Chapter III.III “Portuguese Overview”.  
 
Table 10: Number of active substances studied by chemistry and biotechnological origin 
(2006-2012). Adapted from source [32]. 
 
Table 11: Number of clinical trials promoted by Pharmaceutical Industry and Academical 
Researchers (2006-2012). Adapted from source [32]. 
 
Status of the sponsor 2006 2007 2008 2009 2010 2011 2012 
Pharmaceutical Industry (commercial) 145 127 139 103 101 82 112 
Academical (non commercial) 8 5 7 12 6 6 6 
Total (CTA submitted and valid) 153 132 146 115 107 88 118 
% Pharmaceutical Industry 95% 96% 95% 90% 94% 93% 95% 
 
Table 12: Number of substantial changes of approved clinical trials (2006-2012). Average time 
of decision in the same period. Adapted from source [32]. 
 
 
 
 
 
 
 
Origin of the Active substance(s) of the IMP(s) 
being tested 2006 2007 2008 2009 2010 2011 2012 
Chemical origin 107 103 102 75 72 54 76 
Biological / Biotechnological origin 41 29 41 34 26 26 37 
Chemical & Biological / biotechnological origin 5 0 3 6 9 8 5 
Total (CTA submitted and valid) 153 132 146 115 107 88 118 
% of Biotechnological Active Substances 30% 22% 30% 35% 33% 39% 36% 
Substantial amendments notified for 
authorization  2006 2007 2008 2009 2010 2011 2012 
Notifications Submitted (N)  64 97 158 244 305 327 332 
Notifications Authorized (N)  52 84 155 218 259 267 282 
Notifications Not Authorized (N)  NA 0 0 0 1 0 2 
Average time for authorization (Days)  NA 38 25 24 20 23 23 
% In time  NA 60% 97% 96% 100% 99% 99% 
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II-Personality interviewed  
 
Maria Luísa Ribeiro, PhD, Director of Clinical Trials Centre (CTC) of AIBILI (Association for 
Innovation and Biomedical Research on Light). 
 
III-Short Biography of the Personalities referenced in this dissertation 
 
James Lind 
 
James Lind (the cover photograph [50]) was born in Edinburgh in 1716. He was a Scottish 
physician and was a pioneer of naval hygiene. In 1731, he registered as an apprentice at the 
College of Surgeons in Edinburgh and in 1739 became a surgeon's mate. In 1747, while 
serving as surgeon on HMS Salisbury, he carried out experiments to discover the cause of 
scurvy, whose symptoms included loose teeth, bleeding gums and haemorrhages. So, by 
conducting the first ever clinical trial, he developed the theory that citrus fruit cured scurvy 
that allowed that scurvy disappeared almost completely from the Royal Navy [12].  
After this experiment, in 1748, Lind retired from the navy and went to Edinburgh University 
to take professional qualifications and practiced privately as a physician. In 1753, he published 
'A Treatise of the Scurvy' and in 1757 'An Essay on the Most Effectual Means of Preserving 
the Health of Seamen in the Royal Navy'. In 1758, he was appointed chief physician of the 
Royal Naval Hospital at Haslar in Gosport where he investigated the distillation of fresh 
water from salt water for supply to ships. In 1763, Lind published work on typhus fever in 
ships and in the 1768 publication 'An Essay on Diseases Incidental to Europeans in Hot 
Climates' he summarised the prevalent diseases in each colony and gave advice on avoiding 
tropical infections. Lind died in 1794 in Gosport [12].  
 
Maria Luísa Ribeiro 
 
With a Medical Doctor degree in Ophtalmology and a Master in Ophthalmology by 
University of Coimbra is the director of the Clinical Trial Centre (CTC) of AIBILI since 1994 
and the main researcher since 2003 until present, in the same institution. Until that was 
Ophthalmologist resident in the Dept of Ophthalmology at University Hospital of Coimbra 
in which Luísa Ribeiro has the position of sub-investigator since 1996 [51]. 
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Her clinical and research experience gives her the possibility of coordinating and performing 
a lot of clinical trials with fairly good results and with a fantastic recruitment rate which 
reveals an efficient work and which brings recognize and prestige for the CTC of AIBILI [51]. 
Her love for the research and sharing of scientific knowledge have made that, since the 
beginning of her career, she has been participated and contribute for a large number of 
publication and communications in various areas like diabetic retinopathy and macular edema 
and even performed some courses like “Introductory course to Clinical Research” [51]. 
   
Luís Almeida 
“CEO at Luzitin SA (www.luzitin.pt), Managing Partner at Blueclinical Ltd 
(www.blueclinical.com) and Managing Partner at ARC Publishing (www.arc-publishing.org). 
Director of the PharmaTrain-affiliated Masters and Post-Graduate Courses on 
Pharmaceutical Medicine (pharmaceutical-medicine.pt), and Vice-Director of the Doctoral 
Programme on Health Sciences and Technologies, University of Aveiro, Portugal.  
Specialist in Clinical Pharmacology and Pharmaceutical Medicine, Luis Almeida has over 20 
years of experience in drug development.  
With a Medical Doctor degree and a PhD degree in Medicine by the University of Porto, 
Luis Almeida was the Director of the Medical and Regulatory Affairs Department of Zyma 
Farmacêutica Portuguesa (CIBA Group) between January 1990 and April 1996. Then, he 
joined BIAL (Portela & Co SA), as Head of Clinical Research and Deputy R&D Director. 
During his 13-year career at BIAL he was responsible for setting up a phase I unit for studies 
in healthy volunteers and for defining and supervising the clinical development programmes 
of BIAL’s new chemical entities. Over 100 clinical trials were conducted under his 
responsibility. 
Luis Almeida is inventor/co-inventor of 6 international patents, and author/co-author of over 
65 papers in peer-reviewed journals, 125 abstracts/proceedings, 2 book chapters, and over 
200 posters/oral communications at scientific meetings. 
Specialties: Pharmaceutical medicine, clinical pharmacology, clinical research, drug 
development, electronic health records, photodynamic therapy, personalized medicine. 
He has been playing different jobs and functions:   
- Managing Partner- Blueclinical Ltd: Drug R&D consultancy, phase 1 clinical trials (including 
bioavailability/bioequivalence) and clinical research management; 
- Managing Partner-ARC Publishing: Statistics and scientific writing services. Scientific 
publishing; 
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- CEO- Luzitin, S.A.: Member of the Management Team of Luzitin SA, with the role of Chief 
Executive Officer (CEO). Luzitin’s Mission is to investigate and develop innovative 
compounds to be used in Photodynamic Therapy (PDT) or Photodynamic Diagnosis (PDD) 
of cancer and other diseases, thus contributing to the human wellness; 
- Director, Masters and Post-Graduate Course on Pharmaceutical Medicine-Health Sciences 
Department, University of Aveiro, Portugal: Management of a Training Programme on 
Pharmaceutical Medicine at the University of Aveiro. The programme is recommended by 
the AMPIF (Portuguese Association of Pharmaceutical Medicine Physicians) and affiliated at 
the IMI PharmaTrain. The Training Programme is organized in modules aligned with the 
PharmaTrain's European Training Syllabus for Pharmaceutical Medicine. The teaching staff is 
composed by experts from the Portuguese and foreign universities, regulatory authorities, 
pharmaceutical, biotechnology and medical devices industries, and contract research 
organisations (CROs); 
- Head of Clinical Research and R&D Deputy Director-BIAL (Portela & Co, SA): Responsible 
for the clinical development programme of 6 new drugs, including eslicarbazepine acetate, 
nebicapone, etamicastat, trans-resveratrol and opicapone; 
- Director, Medical and Regulatory Affairs Department-Zyma Farmacêutica Portuguesa Lda 
(CIBA Group): Deputy Managing Director; member of the Executive Committee and 
Marketing Committee; management of medical affairs, regulatory affairs and clinical 
development; 
- Medical Advisor-CIBA Vision; 
- Medical Advisor-Zyma Farmacêutica Portuguesa, Ltd; 
- General Medical Internship-Hospital S. Joao”. 
 
In linkedin- http://www.linkdin.com/in/jluisalmeida at 01/07/2013 [52]. 
 
 
IV-Quality Management in Clinical Research 
 
All clinical research related activities are performed under a Quality Management System. 
The sponsor is ultimately responsible for the quality and the integrity of the trial data but all 
sites should have their own system for quality control and quality assurance [53].  
The QMS aims to document and standardize, by means of written Standard Operating 
Procedures (SOP), all the critical clinical research activities, in order to maximize the 
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efficiency of the processes and to assure full compliance with good clinical practices and the 
legal and ethical requirements [45].  
There are important documents like Trial Master File (TMF) that is kept by the sponsor and 
has relevant information about clinical trials. The investigator must keep the Investigator Site 
File (ISF) of essential documents that allows the inspectors to access how the trial was done 
and the quality of data and show whether the trial followed the relevant EU directives. 
These documents should be generated and on file before the trial starts and any new 
information must add to the files during the trial to show that is documented as it becomes 
available [53]. 
The documentation is very important and all documents have to be written, authorized and 
should [53]: 
- Be complete, legible, genuine, traceable to a specific trial and readily available; 
- Not be altered without permission and creation of an audit trail; 
- Keep a current version at each point of use; 
- Remove obsolete versions from circulation, but keep copies for reference; 
- Review the procedures regularly; 
- Inform staff of any change or any new ones; 
- Keep records that make it possible to trace which version of a SOP was current at 
any given time; 
- Not be copied without control, without the registry of the number and location of 
each copy and without the guarantee that the copy is certified for accuracy, 
completeness, isn’t lost or changed; 
- Be restrictive access, only to authorized people. 
A specific person should be responsible for the documentation and their storage in order to 
guaranty all previous parameters and the correct storage (in adequately facilities and during 
the regulated time) [53]. 
Proper QMS implies consequent implementation of the Quality Assurance, through planned 
and systematic action, to provide adequate confidence that the clinical trial and the 
documentation will satisfy given quality requirements. These actions should be checked by 
someone independent of work (the Quality Assurance Officer) [54]. 
A major part of the quality assurance is the Quality Control that is “the operational 
techniques and activities that are used to satisfy quality requirements” [54]. 
All these three levels of organization of quality activities are very important to production 
quality and to guaranty that the clinical trial and its results are complies with the 
requirements and that its data are reliable. 
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V-Case studies of Clinical Research in Portugal 
 
AIBILI 
 
Association for Innovation and Biomedical Research on Light and Image is a Research 
Technology Organization (RTO) in the health area dedicated to the development and testing 
of new products for diagnostic imaging and medical therapy [51]. 
AIBILI is the Coordinating Centre of the European Vision Institute Clinical Research 
Network – EVICR.net that is a network of European Ophthalmological Clinical Research 
Sites, dedicated to perform clinical research in ophthalmology with the highest standards of 
quality, following the European and International Directives for Clinical Research according 
to harmonized SOPs. At present, EVICR.net has 76 Clinical Site Members from 16 European 
Countries [51]. 
AIBILI has been recognized in 2010 as a Champalimaud Translational Centre for Eye 
Research by the Champalimaud Foundation (C-TRACER) for its activities in translational eye 
research. The Champalimaud Foundation has been progressively establishing a network of C-
TRACERs involving major eye research centres looking for collaboration in a global 
perspective. This network is of major relevance to AIBILI because it brings together under 
the Champalimaud Foundation three major eye research institutions in the World and 
creates links between three major continents, Asia, Europe and South America [51]. 
AIBILI is organized in Research Centres and Supporting Units where highlight Coimbra 
Coordinating Centre for Clinical Research (4C) and CTC.  
The 4C is a qualified structure to support Researcher-Driven and Industry-Sponsored clinical 
trials activities according to ICH GCP and the EU Clinical Trials Directives. 4C permanent 
staff includes five study managers, one statistician, one informatics specialist and one 
administrative secretary [8]. 
CTC has dedicated facilities and the most modern ophthalmological equipment. Permanent 
staff includes three medical doctors, one pharmacist, three technicians for diagnostic 
procedures, six study coordinators and two administrative secretaries. 20 other medical 
doctors, three technicians for diagnostic procedures and four nurses collaborate regularly in 
the CTC activities [8]. 
The professional organization of the CTC and its convenient location, next to the University 
Hospital of Coimbra and the Celas Unit Health Administration of the Central Region of 
Portugal, are a guarantee of efficient recruitment and that the deadlines are successfully met 
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and in compliance with the ICH Good Clinical Practice Guidelines. As we can analyze in the 
graphic below, AIBLI has an efficient recruitment.  
 
 
 
 
 
 
 
Figure 38: Recruitment rate (2007-2011). Recruitment rate in clinical trials is very high (% of planned). 
In 2011 147% of the planed patients were included. Reproduced from source [8]. 
 
The CTC is certified by ISO 9001 to perform clinical trials, thus guaranteeing the continual 
improvement ICH-GCP compliance. CTC is also certified as Clinical Site of Excellence by 
the European Vision Institute Clinical Research Network (Clinical Site nº 1), that is a clinical 
trial centre in ophthalmology that complies with ICH GCP Guidelines with written SOPs, 
has the necessary equipment and personnel to perform clinical trials and has proven 
expertise and scientific publications in this area. 
The number of ongoing clinical trials has been increased. During 2012 it had 11 researcher-
sponsored clinical trials ongoing and 17 industry-sponsored clinical trials [51]. 
 
 
 
 
 
 
 
Figure 39: Initiated and ongoing clinical trials (2007-2011). The number of ongoing clinical trials has 
been increased. Adapted from source [8]. 
 
The main factors for the success are establishing an organization dedicated to clinical 
research consisting by a qualified team, with vanguard equipment and fulfilling the legal and 
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quality requirements and also the integration of international research networks and the 
international recognized resulting of the publications. 
As a result, AIBILI has great operational results: 
 
 
 
 
 
 
 
Figure 40: Operational results (2007-2011). Operational results are the result of the difference 
between operating income and costs (thousands of €). Adapted from source [8]. 
 
This represents also a great advantage to the National Health System that can save much 
money. For example, a clinical trial related to age macular degeneration, that has treated and 
followed 12 patients, will save €100000 to the budget of Health National System [8]. 
 
Blueclinical 
 
Blueclinical is a recent player. Its action plan can be divided into three main activities focused 
on clinical research:  
- R&D consultancy: it provides expert advice and supporting institutions and 
businesses in the development of their projects with a view to the marketing 
[45]: 
- Analysis of business plans, preparation and implementation of 
pharmaceutical, preclinical, clinical and regulatory development plans of 
new drugs, medical devices and other health products; 
- Preparation and monitoring of scientific and regulatory advice with 
INFARMED and foreign regulatory authorities; 
- Planning and supervision of pharmaceutical development and analytical 
methods; 
- Definition and supervision of the implementation of the nonclinical 
development plan; 
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- Preparation of the investigator's brochure and the investigational medicinal 
product dossier; 
- Definition and supervision of the clinical development plan; 
- Ethics approval and regulatory approval for clinical studies; 
- Portfolio selection support; 
- Support in the preparation of the business plan and application for funding.  
Its mission is developing activities of “Translational Medicine” in Portugal, 
through support for institutions and companies (especially start-ups) in their 
I&D projects [29]. 
- Clinical Research Site Management Organization: the objective is to ensure 
successful research in the research centres supported by Blueclinical, promoting 
their growth, efficiency gain and achieving a reputation for excellence in clinical 
research through the creation of highly motivated and organized research teams, 
who are focused on complying with all applicable legal requirements and the 
best ethical and quality standards. With this help, the institutions can improve 
their structural and administrative organization, which is the major limitation to 
the efficiency of clinical research [45].  
- Blueclinical Phase I: clinical research unit of human pharmacology located at 
Hospital da Prelada, Oporto. It focuses on the conduction of phase I studies and 
early proof-of-concepts studies in healthy subjects and in selected patient 
populations. Its experienced staff performs studies like tolerability and 
pharmacokinetics, drug interactions, food effect and bioavailability/ 
bioequivalence studies [45]. The unit has 650 m2 and it has a team of 26 people 
(including 7 doctors and 10 nurses) [29]. 
The creation of this company was born of one gap in clinical research in Portugal, related to 
phase I clinical trials and the research in healthy subjects. The lack of centres of excellence 
to perform clinical trials and theirs organizational deficit was also in the origin of Blueclinical.   
Its staff is highly experienced in drug R&D planning (preparing and submitting the 
documentation of studies to the authorities) and in conducting clinical trials of any phase. Its 
technical and scientific skills are unique in the Portuguese landscape and these places 
Blueclinical on the front line of clinical research in Portugal [45].  
With the networking of knowledge which is being constructed by Blueclinical, this company 
will be briefly recognized as a partner to take into account at the international level, for an 
excellence clinical research [29].  
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CHUC 
 
The University Hospital Centre of Coimbra was created in March 2011 with the fusion of 
the University Hospital of Coimbra, Hospital Centre of Coimbra and Psiquiatric Hospital 
Centre of Coimbra in a total of eight hospitals (two general hospitals, two maternities, three 
psychiatric hospitals and one paediatric hospital) [55]. In total, it has 7800 employees, 1976 
beds and it represents 10% of hospital expenditure in the country and 10% of the GNP of 
“Baixo Mondego” [46]. 
Concerning clinical trials, CHUC has extraordinary conditions to perform clinical trials. It 
has all medical facilities and a high number of patients, which translates annually in 66500 
hospitalizations, 50000 surgeries and 880000 external consultations. During the period 
between 2006 and 2011 CHUC was in the first place in the ranking of the number of clinical 
trials per site in Portugal, with an average of 158 clinical trials. In 2012 they performed 176 
clinical trials, a third of the total performed in Portugal. The objective is to allow access of 
their patients to innovative medicines and treatments in an earlier phase and also the 
possibility of placing these treatments, medicines, diagnostics methods and also medical 
devices on the market. CHUC has also a great recruitment rate in clinical trials. For some of 
MCT performed, CHUC was the site that recruited more patients and, in other clinical 
trials, CHUC was the site that included the first patient for a clinical trial [46]. 
For that, Coimbra Research was created to help the affirmation of Coimbra as the 
Portuguese Health Capital and with the support and work of various institutions and 
companies of the region (Biocant, Instituto Pedro Nunes, Critical Health, MedicineOne and 
Bluepharma) [46].  
Furthermore, CHUC will receive the first centre of clinical trials of phase I in Portugal. This 
centre is a big bet on the clinical trials and in innovation. With that, Portugal, Coimbra, 
researchers and patients will be facing the most recent innovations. This project will be 
working in spaces that were unoccupied, after the CHUC reorganization, so the investment 
will be small. It has tremendous advantages like the development of phase I clinical trials in 
Portugal, the access to new medicines in early phases, the creation of employees and also 
the improvement of international visibility. This centre will complete the supply of CHUC 
that has been performed clinical trials of phase II, III and IV. This centre has also the 
objective of consolidating the leading position in areas such as neurology, neuroscience and 
cardiology [44]. 
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CHUC will also create a Centre of Integrated Responsibility dedicated to clinical research in 
order to achieve more autonomy and flexibility to adapt the technical and human resources 
to the necessities [44]. 
 
Eurotrials 
 
Eurotrials is a CRO founded in Lisbon in 1995. It specialises in clinical research and scientific 
consultancy in the health area. It has several areas of activity including R&D and CT. With 
R&D activity, Eurotrials has the aim of improving health research while establishing a link 
with the market. It has all the competences and experience needed to operate in the drug 
development, analysing projects and drafting plans for strategic and regulatory development. 
Related to CT, they develop and monitor CT in Europe and Latin America [56]. 
Eurotrials has also an independent department of quality with vast experience in quality 
control and quality assurance, including GCP audits. In addition to outsourcing, they ensure 
that all work of the Eurotrials departments complies with  ISO 9001:2008, the legislation in 
different countries, the rules of good clinical practice (ICH-GCP and GCP Directive) and any 
other applicable regulations [56]. 
After 18 years, Eurotrials is a partner of reference for clinical research and scientific 
consultancy in health area in Portuguese-speaking countries. The company’s success stands 
on: creativity in finding solutions, unique technology, multidisciplinary expertise, solid 
experience and quality. It is qualified to participate in all the steps of any clinical, translational 
or epidemiological research project, from the initial research question to the final output 
[56]. 
Eurotrials counts with a diversified and interdisciplinary team in order to meet its customers’ 
needs. It is a link between pharmaceutical industry, sites and hospitals, universities, CROs, 
foundations and institutions, financial groups, consultancy firms, health regulatory authorities, 
health professionals and patient associations [56]. 
Eurotrials has also an important role of sharing experience and knowledge. It has been 
developing training programs and activities that are tailored to meet the needs of different 
groups, in close collaboration with the pharmaceutical industry, medical societies and clinical 
research departments. More than 2200 health professionals have participated in 1520 hours 
of activities. In CT area we can emphasize the course of monitor of CT whose mains are: to 
recognize the importance of CT, to understand the cycle of clinical research and CT, to 
understand all process of regulatory submission, to meet national and international laws and 
regulations and to meet the stakeholder of CT and their responsibilities [56]. 
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Portuguese Clinical Research Infrastructure Network 
 
PtCRIN’s Portuguese Clinical Research Infrastructure Network is a national research 
infrastructure hosted by Nova Medical School and Portuguese Society of Pharmacology. The 
aim is to facilitate and improve quality in clinical research and encourage national and 
international research collaboration for the benefit of patients, citizens and the healthcare 
system. PtCRIN will strengthen and link several existing centres and will actively promote 
collaboration between them [57]. It will be the hub to support multi centre studies and to 
attract to Portugal international academic clinical trials managed by ECRIN (Europe Clinical 
Research Infrastructure Network), whose aim is to support multinational research by 
promoting a network dedicated to improving the health of patients through clinical research. 
ECRIN synergizes the capacities and capabilities of national research and harmonize 
European clinical research [58]. 
PtCRIN focuses on academic clinical trials because they provide answers to crucial clinical 
questions, they are at the practical end of translational research, they promote an 
environment of know-how and trial efficiency (which in turns attracts the industry trials) and 
they are a sector that needs support. Taking advantage of ECRIN support, the objective is 
improving the number of academic CTs led by Portuguese investigators that, at the moment, 
is negligent (2-4/year). The aim is to develop and organize specific infrastructures to provide 
services and support the investigator to implement CT and comply with ICH-GCP 
guidelines, European CT Directive and national legislation. These services will be available to 
the clinicians willing to undertake academic clinical trials [57].  
With the PtCRIN integration in ECRIN, Portugal has already obtained some funds which can 
capacitate Portuguese clinical research. PtCRIN will be able to bring additional funds from 
the EU, international health industry and other sponsors [57]. 
There is already a network of institutions and hospitals and also a formation program to 
improve the competencies of investigators, nurses, study coordinators and other health 
professionals, and to guarantee their continuing education. 
 
New law proposal 
 
In May 2013 a new law proposal, related to clinical research, was approved in the council of 
ministers, without any votes against. The main goal is the transversal application of the 
ethical evaluation through the regulation of the approval and performance of clinical trials 
91 
process. The appreciation regime of CEIC becomes generalized as well as the establishment 
of sponsors, researchers and sites liability [47]. 
The same proposal also provides the creation of a National Registry of Clinical Trials. The 
objective is to improve the authorization process and the transmission of all relevant 
information. On the other hand it will improve the access to information about which clinical 
trials are performed in Portugal for general society and health professionals [47]. 
The most relevant aspects are [49]: 
- Clinical research regulation since the evaluation of the performed processes, 
advertise and sharing of resources; 
- Introduction of a glossary of clinical trials that is fundamental for necessary regulatory 
framework; 
- Streamline approval processes of clinical trials; 
- Clarify the role of CEIC and CECs creating a networking of ethical Commissions, 
standardizing procedures and sharing specialized resources, consultancy and 
reciprocal recognition of opinions; 
- Horizontal application of ethical evaluation by the generalization of evaluation and 
approval processes; 
- Strengthen the role of the CEIC; 
- Create obligations for responsible advertising of clinical trials with a correct 
identification, interpretation and control; 
- Protect voluntary participants; 
- Creation of a National Registry of Clinical Trials and the obligation of registration of 
all stakeholders in order to obtain a complete platform of all clinical trials and the 
improvement of stakeholders interaction and the development of quality clinical 
research.   
This is the beginning of the recognition of the importance of clinical research by the 
government and political leaders. This can mean the beginning of clinical research 
recognition as relevant strategy for Portugal improvement. This can be the beginning of the 
necessary supportive governmental framework and it is good news for clinical research.  
 
PNEC 
 
National Platform for Clinical Trials is a portal with relevant information related to clinical 
trials. In this portal we can find information about laws, the procedures to perform a clinical 
trial and statistics about Portuguese clinical trials. The portal is also an open platform where 
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the interaction between the different partners of clinical research (CROs, regulatory 
authorities, sponsors, researchers, sites and patients) is promoted [25]. 
The main objectives are identifying the problems for the performance of clinical trials in 
Portugal, promoting clinical research, increasing the number of clinical trials and developing 
centres of excellence to perform clinical trials in Portugal. The final objective is encouraging 
the development of high quality research for the benefit of patients [25]. 
This portal also gives us information about the activities organized by PNEC, INFARMED, 
CEIC and other related organizations. It is a connection point between these organizations 
and their websites [25]. 
With the objective of promoting clinical trials and clinical research, this site also has 
information about possible formations that improve the competences and Curriculum Vitae of 
the health professions that have interest in this area [25]. 
PNEC also allows the electronic submission of amendments in the marketing authorization. 
With this platform, Portugal was one of the first countries with the option to submit 
amendments notifications via internet. Companies can also follow the status of their 
requests by using this platform [25]. 
But the goal of PNEC is to go further and facilitate the submission of new clinical trials and 
projects, through electronic submission of the documentation. The implementation project 
of this portal is still ongoing and is important its promotion through of [8]: 
- Centralization of all electronic submission process “one-stop-shop”; 
- Promotion of information about ongoing clinical trials and recruiting clinical trials in 
order to facilitate the recruitment; 
- Certification of sites and researchers; 
- Promotion of data about the activity of sites and researchers in order to promote 
the performance and competitiveness in Portugal. 
 
